

**TITLE 7 HEALTH**  
**CHAPTER 34 MEDICAL USE OF CANNABIS**  
**PART 2 ADVISORY BOARD RESPONSIBILITIES AND DUTIES**

**7.34.2.1 ISSUING AGENCY:** New Mexico Department of Health, ~~Public Health Division~~Medical Cannabis Program.

[7.34.2.1 NMAC - Rp, 7.34.2.1 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.2.2 STATUTORY AUTHORITY:** ~~These~~The requirements set forth herein are promulgated by the secretary of the department of health; pursuant to the authority granted under ~~the Department of Health Act, Section 9-7-6E6 (E) NMSA 1978,~~ and the Lynn and Erin Compassionate Use Act, ~~Sections 26-2B-1 through 26-2B-7, (et seq. NMSA 2007), 1978.~~

[7.34.2.2 NMAC - Rp, 7.34.2.2 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.2.3 SCOPE:** This part governs the membership, duties, responsibilities and public hearing proceedings of the medical cannabis advisory board.

[7.34.2.3 NMAC - Rp, 7.34.2.3 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.2.4 DURATION:** Permanent.

[7.34.2.4 NMAC - Rp, 7.34.2.4 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.2.5 EFFECTIVE DATE:** ~~December 30, 2010~~ July 1, 2014, unless a later date is cited at the end of a section.

[7.34.2.5 NMAC - Rp, 7.34.2.5 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.2.6 OBJECTIVE:** The objective of this part is to establish membership, duties, responsibilities, and public hearing procedures that govern the medical cannabis advisory board proceedings.

[7.34.2.6 NMAC - Rp, 7.34.2.6 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.2.7 DEFINITIONS:**

**A.** “**Act**” means the Lynn and Erin Compassionate Use Act, NMSA 1978, Sections 26-2B-1 through 26-2B-7.

**B.** “**Administrative review committee**” means an intra-department committee that reviews qualified patient or primary caregiver application denials, licensed producer denials, or the imposition of a summary suspension. ~~The administrative review committee shall consist of the medical director for the department’s public health division (or that person’s designee); the director of the public health division (or that person’s designee); and the chief of the infectious disease bureau of the department’s public health division (or that person’s designee).~~

**C.** “**Administrative withdrawal**” means the procedure for the voluntary withdrawal of a qualified patient or primary caregiver from the medical cannabis program.

**D.** “**Adequate supply**” means an amount of cannabis, derived solely from an intrastate and licensed source and in a form approved by the department, that is possessed by a qualified patient or collectively possessed by a qualified patient and the qualified patient’s primary caregiver, that is determined by the department to be no more than reasonably necessary to ensure the uninterrupted availability of cannabis for a period of three (3) months. ~~An adequate supply shall not exceed six (6) ounces of useable cannabis, and with a personal production license only, four (4) mature plants and twelve (12) seedlings, or a three (3) month supply of topical treatment. An amount greater than six (6) ounces of useable cannabis may be allowed, at the department’s discretion, upon proof of special need as evidenced by a practitioner letter explaining why a larger dose is indicated. Any such allowance shall be reviewed for approval by a medical director designated by the department, who shall consider standards for exceptions to the adequate supply requirements that are approved by the advisory board. A qualified patient and primary caregiver may also possess cannabis seeds, or ninety (90) consecutive calendar days.~~

**E.** “**Adverse action**” includes the denial of any application, immediate revocation of the qualified patient or primary caregiver’s registry identification card, licensed producer revocation, referral to state or local law enforcement and loss of all lawful privileges under the act.

**F. D.** “**Advisory board**” means the medical cannabis advisory board consisting of eight (8) practitioners representing the fields of neurology, pain management, medical oncology, psychiatry, infectious disease, family medicine and gynecology.

**GE.** **“Applicant”** means any person applying ~~to participate for enrollment or re-enrollment~~ in the medical ~~use of~~ cannabis program as a qualified patient, primary caregiver or licensed producer.

**F.** **“Approved laboratory”** means a laboratory that has been approved by the department specifically for the testing of cannabis, concentrates and cannabis derived products.

**G.** **“Batch”** means, with regard to usable cannabis, a ~~homogenous, identified quantity of cannabis harvested during a specified time period from a specified cultivation area, and with regard to concentrated and cannabis-derived product, means an identified quantity that is uniform, that is intended to meet specifications for identity, strength and composition, and that is manufactured, packaged and labeled during a specified time period according to a single manufacturing, packaging, and labeling protocol.~~

**H.** **“Cannabis”** means all parts of the plant cannabis sativa and cannabis indica, whether growing or not; ~~and the resin extracted from any part of the plant, and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its resin.~~

**I.** **“Consent to release of medical information form”** **“Cannabis-derived product”** means a signed product, other than cannabis itself, which contains or is derived from cannabis, not including hemp.

**J.** **“Concentrated cannabis-derived product (“concentrate”)** means a cannabis-derived product that is manufactured by a mechanical or chemical process that separates any cannabinoid from the cannabis plant, and that contains no less than thirty-percent (30%) THC by weight.

**K.** **“Courier”** means a person or entity that transports usable cannabis within the state of New Mexico from a licensed non-profit producer to a qualified patient or primary caregiver ~~authorization form to release specific medical information relating to the use of cannabis.~~

**JL.** **“Debilitating medical condition”** means:

- (1) cancer;
- (2) glaucoma;
- (3) multiple sclerosis;
- (4) damage to the nervous tissue of the spinal cord, with objective neurological indication of intractable spasticity;

(5) epilepsy;

(6) positive status for human immunodeficiency virus or acquired immune deficiency syndrome;

(7) admission into hospice care in accordance with rules promulgated by the department; or

(8) any other medical condition, medical treatment or disease as approved by the department which

results in pain, suffering or debility for which there is credible evidence that medical use cannabis could be of benefit.

~~**K.** **“Deficiency”** means a violation of or failure to comply with a provision of these requirements.~~

~~**L.** **M.** **“Department”** means the department of health or its agent.~~

~~**M.** **“Division”** means the public health division of the department of health.~~

~~**N.** **“Facility”** means any building, space or grounds licensed for the production, possession ~~and,~~ testing, manufacturing or distribution of cannabis ~~in any form, concentrates or cannabis-derived products.~~~~

~~**O.** **“Intrastate”** means existing or occurring within the state boundaries of New Mexico.~~

~~**P.** **P.** **“Laboratory applicant”** means a laboratory that seeks to become an approved laboratory, or that seeks renewal of approval as an approved laboratory, in accordance with this rule.~~

~~**Q.** **“License”** means the document issued by the department granting the legal right to produce ~~and~~ distribute medical cannabis for a specified period of time.~~

~~**QR.** **“Licensed producer”** means a person or entity licensed to produce medical cannabis.~~

~~**RS.** **“Licensure”** means the process by which the department grants permission to an applicant to produce ~~or possess~~ cannabis.~~

~~**S.** **T.** **“Lot”** means an identified portion of a batch, that is uniform and that is intended to meet specifications for identity, strength, and composition; or, in the case of a cannabis-derived product or concentrate, an identified quantity produced in a specified period of time in a manner that is uniform and that is intended to meet specifications for identity, strength, and composition.~~

~~**U.** **“Male plant”** means a male cannabis plant.~~

~~**V.** **“Manufacture”** means to make or otherwise produce cannabis-derived product or concentrate.~~

~~**W.** **“Manufacturer”** means a business entity that manufactures cannabis-derived product, that has been approved for this purpose by the medical cannabis program.~~

~~**X.** **“Mature female plant”** means a harvestable female cannabis plant that is flowering.~~

~~**FY.** **“Medical cannabis program”** means the administrative body of the ~~New Mexico public health division~~ department charged with the management of the medical cannabis program ~~and enforcement of program~~~~

~~regulations~~, to include issuance of registry identification cards, licensing of producers, ~~and regulation of manufacturing and distribution systems, administration of public hearings and administration of informal administrative reviews.~~

~~UZ.~~ **“Medical cannabis program manager”** means the administrator of the ~~New Mexico department of health, public health division~~ medical cannabis program who holds that title.

~~VAA.~~ **“Medical director”** means a medical practitioner designated by the department to determine whether the medical condition of an applicant qualifies as a debilitating medical condition eligible for enrollment in the program, ~~and to perform other duties.~~

~~WBB.~~ **“Medical provider certification for patient eligibility form”** means a written certification form provided by the medical cannabis program signed by a patient's practitioner that, in the practitioner's professional opinion, the patient has a debilitating medical condition as defined by the act or this part and would be anticipated to benefit from the use of cannabis.

~~XCC.~~ **“Minor”** means an individual less than eighteen (18) years of age.

~~YDD.~~ **“Paraphernalia”** means any equipment, product, or material of any kind that is primarily intended or designed for use in compounding, converting, processing, preparing, inhaling, or otherwise introducing ~~cannabis or its derivatives~~ into the human body.

~~Z.~~ ~~Participant~~~~EE.~~ **“Patient enrollment/re-enrollment form”** means the registry identification card application form for ~~adult-qualified~~ patient applicants provided by the medical cannabis program.

~~AAF.~~ **“Personal production license”** means a license issued to a qualified patient, ~~eighteen (18) years of age or older~~, participating in the medical cannabis program, ~~or to a qualified patient's primary caregiver~~, to permit the qualified patient ~~or primary caregiver~~ to produce medical cannabis for the qualified patient's personal use, consistent with the requirements of this rule.

~~BBGG.~~ **“Petitioner”** means any New Mexico resident or association of New Mexico residents petitioning the advisory board for the inclusion of a new medical condition, medical treatment or disease to be added to the list of debilitating medical conditions that qualify for the use of cannabis.

~~CEHH.~~ **“Plant”** means any cannabis plant, cutting, ~~trimming~~ or clone that has roots or that is cultivated with the intention of growing roots.

~~DDII.~~ **“Policy”** means a written statement of principles that guides and determines present and future decisions and actions of the licensed producer.

~~EEJJ.~~ **“Practitioner”** means a person licensed in New Mexico to prescribe and administer drugs that are subject to the Controlled Substances Act, Sections 30-31-1 *et seq.*, NMSA (1978).

~~FFKK.~~ **“Primary caregiver”** means a resident of New Mexico who is at least eighteen (18) years of age and who has been designated by the qualified patient or ~~patient's~~~~their representative and the patient's~~ practitioner as being necessary to take responsibility for managing the well-being of a qualified patient with respect to the medical use of cannabis pursuant to the provisions of the Lynn and Erin Compassionate Use Act, NMSA 1978, Section 26-2B-1 *et seq.*

~~GLLL.~~ **“Primary caregiver application form”** means the registry identification card application form provided by the medical cannabis program.

~~HHMM.~~ **“Private entity”** means a private, non-profit organization that applies to become or is licensed as a producer and distributor of cannabis, ~~concentrates or cannabis-derived products.~~

~~H~~ ~~NN.~~ **“Proficiency testing”** means testing conducted by the department or its agent to determine the ability of a laboratory applicant or approved laboratory to accurately identify presence, quantity or other factors pertaining to a given analyte.

~~OO.~~ **“Qualified patient”** means a resident of New Mexico who has been diagnosed by a practitioner as having a debilitating medical condition and has received a registry identification card issued pursuant to the requirements of the act or department rules.

~~JPPP.~~ **“Registry identification card”** means a document issued ~~and owned~~ by the department which identifies a qualified patient authorized to engage in the use of cannabis for a debilitating medical condition or a document issued by the department which identifies a primary caregiver authorized to engage in the intrastate possession and administration of cannabis for the sole use of the qualified patient.

~~KKQQ.~~ **“Representative”** means an individual designated as the ~~applicant's~~ or petitioner's agent, guardian, surrogate, or other legally appointed or authorized health care decision maker ~~pursuant to the Uniform Health Care Decisions Act, Sections 24-7A-1 et seq. (NMSA 2007).~~

~~LLRR.~~ **“Secretary”** means the secretary of the New Mexico department of health.

~~MMSS.~~ **“Secure grounds”** means a facility that provides a safe environment to avoid loss or theft.

~~NNTT.~~ **“Security alarm system”** means any device or series of devices capable of alerting law enforcement, including, but not limited to, a signal system interconnected with a radio frequency method such as cellular, private radio signals, or other mechanical or electronic device used to detect ~~and~~ report an emergency or unauthorized intrusion.

~~OOUU.~~ **“Security policy”** means the instruction manual or pamphlet adopted or developed by the licensed producer containing security policies, safety and security procedures, personal safety and crime prevention techniques.

~~PPVV.~~ **“Seedling”** means a cannabis plant that has no flowers.

~~QQ.~~ **“Submission date”** means the date of submission of the last item in an application, petition or proposal.

~~RRWW.~~ **“Segregate”** means to separate and withhold from use or sale batches, lots, cannabis, usable cannabis or cannabis-derived products in order to first determine its suitability for use through testing by an approved laboratory.

~~XX.~~ **“THC”** means tetrahydrocannabinol, the primary psychoactive ingredient in cannabis.

~~YY.~~ **“Technical evidence”** means scientific, clinical, medical or other specialized testimony, or evidence, but does not include legal argument, general comments, or statements of policy or position concerning matters at issue in the hearing.

~~SS.~~ **“Topical treatment”** means a transcutaneous therapeutic cannabis extract formulation.

~~TT~~ ~~ZZ.~~ **“Testing”** means the process and procedures provided by an approved laboratory for testing of cannabis and cannabis derived products, consistent with provisions of this rule.

~~AAA.~~ **“Unit”** means a quantity of usable cannabis, concentrate or cannabis-derived product that is used in identifying the maximum supply that a qualified patient may possess for purposes of department rules.

~~BBB.~~ **“Usable cannabis”** means the dried leaves and flowers of the female ~~cannabis~~ plant and any mixture or preparation thereof ~~cannabis-derived products~~, including ~~ointments~~ concentrates, but does not include the seedlings, seeds, stalks, or roots of the plant.

[7.34.2.7 NMAC - Rp, 7.34.2.7 NMAC, 12/30/2010/7/15/2014]

#### 7.34.2.8 **ADVISORY BOARD MEMBERSHIP REQUIREMENTS AND RESPONSIBILITIES:**

**A. Advisory board membership:** The advisory board shall consist of eight (8) practitioners representing the fields of neurology, pain management, medical oncology, psychiatry, infectious disease, family medicine and gynecology. The practitioners shall be nationally board-certified in their area of specialty and knowledgeable about the medical use of cannabis. The members shall be chosen for appointment by the secretary from a list proposed by the New Mexico medical society.

**B. Duties and responsibilities:** The advisory board shall convene at least twice per year to:

- (1) review and recommend to the department for approval additional debilitating medical conditions that would benefit from the medical use of cannabis;
- (2) ~~recommended~~ recommend quantities of cannabis that are necessary to constitute an adequate supply for qualified patients and primary caregivers;
- (3) accept and review petitions to add medical conditions, medical treatments or diseases to the list of debilitating medical conditions that qualify for the medical use of cannabis and all lawful privileges under the act and implementing rules;
- (4) issue recommendations concerning rules to be promulgated for the issuance of registry identification cards; and
- (5) review conditions previously reviewed by the board and approved by the secretary for the purpose of determining whether to recommend the revision of eligibility criteria for persons applying under those conditions or to review new medical and scientific evidence pertaining to currently approved conditions.

**C. Advisory board membership term:** Each member of the advisory board shall serve a term of two (2) years from the date of appointment by the secretary. No member may be removed prior to the expiration of his or her term without a showing of good cause by the secretary.

**D. Chairperson elect:** The advisory board shall elect by majority vote cast of the eight (8) member board a chairperson and an alternate. The chairperson or alternate shall exercise all powers and duties prescribed or delegated under the act or this rule.

- (1) **Public hearing responsibilities:** The chairperson shall conduct a fair and impartial proceeding, assure that the facts are fully elicited and avoid delay. The chairperson shall have authority to take all measures necessary for the maintenance of order and for the efficient, fair and impartial resolution of issues arising during the public hearing proceedings or in any public meeting in which a quorum of the advisory board are present.

(2) **Delegation of chair**: The chairperson may delegate their responsibility to an alternate. The alternate shall exercise all powers and duties prescribed or delegated under the act or this part.

E. **Per diem and mileage**: All advisory board members appointed under the authority of the act or this part will receive as their sole remuneration for services as a member those amounts authorized under the Per Diem and Mileage Act, Sections 10-8-1 *et seq.*, (NMSA 1978).  
[7.34.2.8 NMAC - Rp, 7.34.2.8 NMAC, ~~12/30/2010~~7/15/2014]

#### 7.34.2.9 PETITION REQUIREMENTS:

A. **Petition requirements**. The advisory board may accept and review petitions from any individual or association of individuals requesting the addition of a new medical condition, medical treatment or disease for the purpose of participating in the medical cannabis program and all lawful privileges under the act. Except as otherwise provided, a petitioner filing a petition shall file the petition and a copy with the medical cannabis program staff by either personal delivery or certified mail. In order for a petition to be processed and forwarded to the advisory board the following information shall be submitted to the medical cannabis program staff.

(1) **Petition format**: Unless otherwise provided by this part or by order of the hearing officer, all documents, except exhibits, shall be prepared on 8 1/2 x 11-inch white paper, printed double-sided, if possible, and where appropriate, the first page of every document shall contain a heading and caption. The petitioner shall include in the petition documents a narrative address to the advisory board, which includes:

(a) petition caption stating the name, address and telephone number of the petitioner and the medical condition, medical treatment or disease sought to be added to the existing debilitating medical conditions;

(b) an index of the contents of the petition, an introductory narrative of the individual or association of individuals requesting the inclusion of a new medical condition, medical treatment or disease to include the individual or association of individuals' relationship or interest for the request whether that interest is professional or as a concerned citizen;

(c) the proposed benefits from the medical use of cannabis specific to the medical condition, medical treatment or disease sought to be added to the existing debilitating medical conditions listed under the act; and

(d) any additional supporting medical, testimonial, or scientific documentation.

(2) **Statement of intent to present technical evidence**: If the petitioner wishes to present technical evidence at the hearing, the petition shall include a statement of intent. The statement of intent to present technical evidence shall include:

(a) the name of the person filing the statement;

(b) the name of each witness;

(c) an estimate of the length of the direct testimony of each witness;

(d) a list of exhibits, if any, to be offered into evidence at the hearing; and

(e) a summary or outline of the anticipated direct testimony of each witness.

B. **Qualified patient applicant petitioner**: If the petitioner is submitting their requests as a potential qualified patient applicant the petitioner shall attach an original medical practitioner's certification for patient eligibility form provided by the medical cannabis program manager or designee which includes the following information.

(1) The name, address, telephone number and clinical licensure of the petitioner's practitioner.

(2) The petitioner's name, date of birth.

(3) The medical justification for practitioner's certification of the petitioner's debilitating medical condition.

(4) The practitioner's signature and date of signature.

(5) The name, address and date of birth of the petitioner.

(6) The name, address and telephone number of the petitioner's practitioner.

(7) A reasonable xerographic copy of the petitioner's New Mexico driver's license or comparable New Mexico state or federal issued photo identification card verifying New Mexico residence.

(8) Documented parental consent if applicable to the petitioner.

(9) If applicable the petitioner's potential debilitating medical condition.

(10) The length of time the petitioner has been under the care of the practitioner providing the medical provider certification for patient eligibility.

(11) The petitioner's signature and date.

(12) A signed consent for release of medical information form provided by the medical cannabis program.

**C. Petitioner confidentiality:** The department shall maintain a confidential file containing the names and addresses of the persons who have either applied for or received a public hearing petition request. Individual names on the list shall be confidential and not subject to disclosure, except:

(1) to authorized employees or agents of the department as necessary to perform the duties of the department pursuant to the provisions of the act or this part;

(2) as provided in the federal Health Insurance Portability and Accountability Act of 1996.

**D. Department notification:** The medical cannabis program manager or designee shall review each petition request and within reasonable time after receipt issue notice of docketing upon the petitioner, each advisory board member, and the advisory board legal counsel. The notice of docketing shall contain the petition caption and docket number, the date upon which the petition was received and scheduling date of the advisory board public hearing. A copy of this rule shall be included with a notice of docketing sent to the petitioner.

**E. Examination allowed:** Subject to the provisions of law restricting the public disclosure of confidential information, any person may, during normal business hours, inspect and copy any document filed in any public hearing proceeding. Inspection shall be permitted in accordance with the Inspection of Public Records Act, NMSA 1978, Sections 14-2-1 *et seq.*, (NMSA 1978), but may be limited by the Health Insurance Portability and Accountability Act of 1996. Documents subject to inspection shall be made available by the medical cannabis program manager, or designee as appropriate. Unless waived by the department, the cost of duplicating documents or ~~tapes~~audio filed in any public hearing proceeding shall be borne by the person seeking the copies.

**F. Notice of withdrawal:** A petitioner may withdraw a petition at any time prior to a decision by the advisory board by filing a notice of withdrawal with the medical cannabis program manager or designee. [7.34.2.9 NMAC - Rp, 7.34.2.9 NMAC, ~~12/30/2010~~7/15/2014]

#### 7.34.2.10 ADVISORY BOARD PUBLIC HEARING PROCEDURES:

**A. Public hearing requirement:** The advisory board shall convene by public hearing at least twice (2) per year to accept and review petitions requesting the inclusion of medical conditions, medical treatments or diseases to the list of debilitating medical conditions. Any meeting consisting of a quorum of the advisory board members held for the purpose of evaluating, discussing or otherwise formulating specific opinions concerning the recommendation of a petition filed pursuant to this rule, shall be declared a public hearing open to the public at all times, unless a portion of the hearing is closed to protect information made confidential by applicable state or federal laws. A petitioner or his or her representative may request to close a portion of the hearing to protect the disclosure of confidential information by submitting their request in writing and having that request delivered to medical cannabis program staff at least forty-eight (48) hours prior to the hearing.

**B. Location of the public hearing:** Unless otherwise ordered by the advisory board, the public hearing shall be held in New Mexico at a location sufficient to accommodate the anticipated audience.

**C. Public hearing notice:** The medical cannabis program manager or designee shall, upon direction from the advisory board chairperson, prepare a notice of public hearing setting forth the date, time and location of the hearing, a brief description of the petitions received, and information on the requirements for public comment or statement of intent to present technical evidence, and no later than thirty (30) days prior to the hearing date, send copies, with requests for publication, to at least one newspaper of general circulation. The program manager or designee may further issue notice of the hearing by any other means the department determines to be acceptable to provide notice to the public.

**D. Public hearing agenda:** The department shall make available an agenda containing a list of specific items to be discussed or information on how the public may obtain a copy of such agenda.

**E. Postponement of hearing:** Request for postponement of a public hearing will be granted, by the advisory board for good cause shown.

**F. Statement of intent to present technical evidence:** Any individual or association of individuals who wish to present technical evidence at the hearing shall, no later than fifteen (15) days prior to the date of the hearing, file a statement of intent. The statement of intent to present technical evidence shall include:

- (1) the name of the person filing the statement;
- (2) indication of whether the person filing the statement supports or opposes the petition at issue;
- (3) the name of each witness;
- (4) an estimate of the length of the direct testimony of each witness;
- (5) a list of exhibits, if any, to be offered into evidence at the hearing; and
- (6) a summary or outline of the anticipated direct testimony of each witness.

**G. Ex parte discussions:** At no time after the initiation and before the conclusion of the petition process under this part, shall the department, or any other party, interested participant or their representatives discuss ex parte the merits of the petitions with any advisory board member.

**H. Public hearing process:** The advisory board chairperson shall conduct the public hearing so as to provide a reasonable opportunity for all interested persons to be heard without making the hearing unreasonably lengthy or cumbersome or burdening the record with unnecessary repetition.

(1) A quorum of the advisory board shall consist of three (3) voting members.

(2) The advisory board chairperson or alternate shall convene each public hearing by:

(a) introduction of the advisory board members;

(b) statutory authority of the board;

(c) statement of the public hearing agenda; and

(d) recognition of the petitioner.

(3) Petitioner comment period. The petitioner or by representative may present evidence to the advisory board. The advisory board shall only consider findings of fact or scientific conclusions of medical evidence presented by the petitioner or by representative to the advisory board prior to or contemporaneously with the public hearing.

(4) **Public comment period:** The advisory board may provide for a public comment period. Public comment may be by written comment, verbal or both.

(a) **Written comment:** Any individual or association of individuals may submit written comment to the advisory board either in opposition or support of the inclusion of a medical conditions, medical treatments or diseases to the existing list of debilitating medical conditions contained under the act. All written comment shall adhere to the requirements of Subsection F of this section.

(b) **Public comment:** Any member of the general public may testify at the public hearing. No prior notification is required to present general non-technical statements in support of or in opposition to the petition. Any such member may also offer exhibits in connection with his testimony, so long as the exhibit is non-technical in nature and not unduly repetitious of the testimony.

**I. ~~Recorded minutes-Recording the hearing:~~** Unless the advisory board orders otherwise, the hearing will be ~~tape audio~~ recorded. Any person, other than the advisory board, desiring a copy of ~~hearing the audio~~ tapes must arrange copying with the medical cannabis program ~~program~~ or designee at their own expense.

[7.34.2.10 NMAC - Rp, 7.34.2.10 NMAC, ~~12/30/20107/15/2014~~]

#### 7.34.2.11 **ADVISORY BOARD RECOMMENDATION TO THE DEPARTMENT:**

**A. Advisory board recommendation:** Upon final determination the advisory board shall provide to the secretary a written report of finding, which recommends either the approval or denial of the petitioner's request. The written report of findings shall include a medical justification for the recommendation based upon the individual or collective expertise of the advisory board membership. The medical justification shall delineate between the findings of fact made by the advisory board and scientific conclusions of credible medical evidence.

**B. Department final determination:** The department shall notify the petitioner within ten (10) days of the secretary's determination. A denial by the secretary regarding the inclusion of a medical conditions, medical treatments or diseases to the existing list of debilitating medical conditions contained under the act shall not represent a permanent denial by the department. Any individual or association of individuals may upon good cause re-petition the advisory board. All requests shall present new supporting findings of fact, or scientific conclusions of credible medical evidence not previously examined by the advisory board.

[7.34.2.11 NMAC - Rp, 7.34.2.11 NMAC, ~~12/30/20107/15/2014~~]

**7.34.2.12 SEVERABILITY:** If any part or application of these rules is held to be invalid, the remainder or its application to other situations or persons shall not be affected. Failure to promulgate rules or implement any provision of these rules shall not interfere with the remaining protections provided by these rules and the act.

[7.34.2.12 NMAC - Rp, 7.34.2.12 NMAC, ~~12/30/20107/15/2014~~]

#### **HISTORY OF 7.34.2 NMAC:**

**Pre NMAC History:** none.

#### **History of Repealed Material:**

7.34.2 NMAC, Advisory Board Responsibilities and Duties (filed 03/19/2008) repealed ~~12/30/20107/15/2014~~.

**NMAC History:**

7.34.2 NMAC, Advisory Board Responsibilities and Duties (filed 03/19/2008) was replaced by 7.34.2 NMAC, Advisory Board Responsibilities and Duties, effective ~~12/30/2010~~07/15/2014.

**TITLE 7 HEALTH**  
**CHAPTER 34 MEDICAL USE OF CANNABIS**  
**PART 3 REGISTRY IDENTIFICATION CARDS**

**7.34.3.1 ISSUING AGENCY:** New Mexico Department of Health, ~~Public Health Division: Medical Cannabis Program.~~

[7.34.3.1 NMAC - Rp, 7.34.3.1 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.3.2 SCOPE:** This rule governs the issuance of registry identification cards to qualified patients and primary caregivers as defined by the Lynn and Erin Compassionate Use Act, 26-2B-3(F) and (G) NMSA 1978. All requirements contained herein are necessary prerequisites to the state's ability to distinguish between authorized use under the act and unauthorized use under the state's criminal laws.

[7.34.3.2 NMAC - Rp, 7.34.3.2 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.3.3 STATUTORY AUTHORITY:** The requirements set forth herein are promulgated by the secretary of the department of health; pursuant to the ~~general~~ authority granted under Section 9-7-6 (E) NMSA 1978, ~~as amended; Section 53-8-1 et seq. NMSA 1978;~~ and the Lynn and Erin Compassionate Use Act, ~~Section 26-2B-1 et seq. NMSA 1978.~~ Although federal law currently prohibits any use of cannabis, the laws of ~~Alaska, California, Colorado, the District of Columbia, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, Oregon, Rhode Island, Vermont and Washington~~ several states permit the medical use and cultivation of cannabis. ~~New Mexico joins this effort to provide for the health and welfare of its citizens.~~ New Mexico adopts these regulations to accomplish the purpose of the Lynn and Erin Compassionate Use Act as stated in Section 26-2B-2 NMSA 1978, "to allow the beneficial use of medical cannabis in a regulated system for alleviating symptoms caused by debilitating medical conditions and their medical treatments," while at the same time ensuring proper enforcement of any criminal laws for behavior that has been deemed illicit by the state.

[7.34.3.3 NMAC - Rp, 7.34.3.3 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.3.4 DURATION:** Permanent.

[7.34.3.4 NMAC - Rp, 7.34.3.4 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.3.5 EFFECTIVE DATE:** ~~December 30, 2010~~ July 1, 2014, unless a later date is cited at the end of a section.

[7.34.3.5 NMAC - Rp, 7.34.3.5 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.3.6 OBJECTIVE:** ~~The objective of this rule is to ensure~~ Ensuring the safe use and possession of cannabis for individuals living with debilitating medical conditions, and the safe possession and administration of cannabis for medical use to those individuals by primary caregivers, as mandated under the Lynn & Erin Compassionate Use Act Sections 26-2B-1 et seq., (NMSA 2007).

[7.34.3.6 NMAC - Rp, 7.34.3.6 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.3.7 DEFINITIONS:**

**A.** "Act" means the Lynn and Erin Compassionate Use Act, NMSA 1978, Sections 26-2B-1 through 26-2B-7.

**B.** "Administrative review committee" means an ~~intra-department committee that reviews qualified patient or primary caregiver application denials, licensed producer denials, or the imposition of a summary suspension. The administrative review committee shall consist of the medical director for the department's public health division (or that person's designee); the director of the public health division (or that person's designee); and the chief of the infectious disease bureau of the department's public health division (or that person's designee).~~

**C.** "Administrative withdrawal" means the procedure for the voluntary withdrawal of a qualified patient or primary caregiver from the medical cannabis program.

**DC.** "Adequate supply" means an amount of cannabis, derived solely from an intrastate ~~and licensed~~ source and in a form approved by the department, ~~that is~~ possessed by a qualified patient or collectively possessed by a qualified patient and the qualified patient's primary caregiver, that is determined by the department to be no more than reasonably necessary to ensure the uninterrupted availability of cannabis for a period of three (3) months. ~~An adequate supply shall not exceed six (6) ounces of useable cannabis, and with a personal production license only.~~

~~four (4) mature plants and twelve (12) seedlings, or a three (3) month supply of topical treatment. A qualified patient and primary caregiver may also possess cannabis seeds, or ninety (90) consecutive calendar days.~~

~~E. “Adverse action” includes the denial of any application, immediate revocation of the qualified patient or primary caregiver’s registry identification card, licensed producer revocation, referral to state or local law enforcement and loss of all lawful privileges under the act.~~

~~F. D. “Advisory board” means the medical cannabis advisory board consisting of eight (8) practitioners representing the fields of neurology, pain management, medical oncology, psychiatry, infectious disease, family medicine and gynecology.~~

~~GE. “Applicant” means any person applying to participate for enrollment or re-enrollment in the medical use of cannabis program as a qualified patient, primary caregiver or licensed producer.~~

~~F. “Approved laboratory” means a laboratory that has been approved by the department specifically for the testing of cannabis, concentrates and cannabis derived products.~~

~~G. “Batch” means, with regard to usable cannabis, a homogenous, identified quantity of cannabis harvested during a specified time period from a specified cultivation area, and with regard to concentrated and cannabis-derived product, means an identified quantity that is uniform, that is intended to meet specifications for identity, strength and composition, and that is manufactured, packaged and labeled during a specified time period according to a single manufacturing, packaging, and labeling protocol.~~

~~H. “Cannabis” means all parts of the plant cannabis sativa and cannabis indica, whether growing or not, and the resin extracted from any part of the plant, and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its resin.~~

~~I. “Consent to release of medical information form “Cannabis-derived product” means a signed product, other than cannabis itself, which contains or is derived from cannabis, not including hemp.~~

~~J. “Concentrated cannabis-derived product (“concentrate”)” means a cannabis-derived product that is manufactured by a mechanical or chemical process that separates any cannabinoid from the cannabis plant, and that contains no less than thirty-percent (30%) THC by weight.~~

~~K. “Courier” means a person or entity that transports usable cannabis within the state of New Mexico from a licensed non-profit producer to a qualified patient or primary caregiver authorization form to release specific medical information relating to the use of cannabis.~~

~~JL. “Debilitating medical condition” means:~~

- ~~(1) cancer;~~
- ~~(2) glaucoma;~~
- ~~(3) multiple sclerosis;~~
- ~~(4) damage to the nervous tissue of the spinal cord, with objective neurological indication of intractable spasticity;~~

- ~~(5) epilepsy;~~
- ~~(6) positive status for human immunodeficiency virus or acquired immune deficiency syndrome;~~
- ~~(7) admission into hospice care in accordance with rules promulgated by the department; or~~
- ~~(8) any other medical condition, medical treatment or disease as approved by the department which results in pain, suffering or debility for which there is credible evidence that medical use cannabis could be of benefit.~~

~~K. “Deficiency” means a violation of or failure to comply with a provision of these requirements.~~

~~L. M. “Department” means the department of health or its agent.~~

~~M. “Division” means the public health division of the department of health.~~

~~N. “Facility” means any building, space or grounds licensed for the production, possession and, testing, manufacturing or distribution of cannabis in any form, concentrates or cannabis-derived products.~~

~~O. “Intrastate” means existing or occurring within the state boundaries of New Mexico.~~

~~P. P. “Laboratory applicant” means a laboratory that seeks to become an approved laboratory, or that seeks renewal of approval as an approved laboratory, in accordance with this rule.~~

~~Q. “License” means the document issued by the department granting the legal right to produce and distribute medical cannabis for a specified period of time.~~

~~QR. “Licensed producer” means a person or entity licensed to produce medical cannabis.~~

~~RS. “Licensure” means the process by which the department grants permission to an applicant to produce or possess cannabis.~~

~~S. T. “Lot” means an identified portion of a batch, that is uniform and that is intended to meet specifications for identity, strength, and composition; or, in the case of a cannabis-derived product or concentrate, an~~

identified quantity produced in a specified period of time in a manner that is uniform and that is intended to meet specifications for identity, strength, and composition.

U. “**Male plant**” means a male cannabis plant.

V. “**Manufacture**” means to make or otherwise produce cannabis-derived product or concentrate.

W. “**Manufacturer**” means a business entity that manufactures cannabis-derived product, that has been approved for this purpose by the medical cannabis program.

X. “**Mature female plant**” means a harvestable female cannabis plant that is flowering.

TY. “**Medical cannabis program**” means the administrative body of the ~~New Mexico public health division department~~ charged with the management of the medical cannabis program and enforcement of program regulations, to include issuance of registry identification cards, licensing of producers, and regulation of manufacturing and distribution systems, administration of public hearings and administration of informal administrative reviews.

UZ. “**Medical cannabis program manager**” means the administrator of the ~~New Mexico department of health, public health division~~ medical cannabis program who holds that title.

VAA. “**Medical director**” means a medical practitioner designated by the department to determine whether the medical condition of an applicant qualifies as a debilitating medical condition eligible for enrollment in the program, and to perform other duties.

WBB. “**Medical provider certification for patient eligibility form**” means a written certification form provided by the medical cannabis program signed by a patient's practitioner that, in the practitioner's professional opinion, the patient has a debilitating medical condition as defined by the act or this part and would be anticipated to benefit from the use of cannabis.

XCC. “**Minor**” means an individual less than eighteen (18) years of age.

YDD. “**Paraphernalia**” means any equipment, product, or material of any kind that is primarily intended or designed for use in compounding, converting, processing, preparing, inhaling, or otherwise introducing cannabis or its derivatives into the human body.

Z. ~~Participant~~EE. “**Patient enrollment/re-enrollment form**” means the registry identification card application form for ~~adult-qualified~~ patient applicants provided by the medical cannabis program.

AAFF. “**Personal production license**” means a license issued to a qualified patient, eighteen (18) years of age or older, participating in the medical cannabis program, ~~or to a qualified patient's primary caregiver~~, to permit the qualified patient ~~or primary caregiver~~ to produce medical cannabis for the qualified patient's personal use, consistent with the requirements of this rule.

BBGG. “**Petitioner**” means any New Mexico resident or association of New Mexico residents petitioning the advisory board for the inclusion of a new medical condition, medical treatment or disease to be added to the list of debilitating medical conditions that qualify for the use of cannabis.

CCHH. “**Plant**” means any cannabis plant, cutting, ~~trimming~~ or clone that has roots or that is cultivated with the intention of growing roots.

DDII. “**Policy**” means a written statement of principles that guides and determines present and future decisions and actions of the licensed producer.

EEJJ. “**Practitioner**” means a person licensed in New Mexico to prescribe and administer drugs that are subject to the Controlled Substances Act, Sections 30-31-1 *et seq.*, NMSA (1978).

FFKK. “**Primary caregiver**” means a resident of New Mexico who is at least eighteen (18) years of age and who has been designated by the qualified patient or ~~patient's~~their representative and the patient's practitioner as being necessary to take responsibility for managing the well-being of a qualified patient with respect to the medical use of cannabis pursuant to the provisions of the Lynn and Erin Compassionate Use Act, NMSA 1978, Section 26-2B-1 *et seq.*

GGLL. “**Primary caregiver application form**” means the registry identification card application form provided by the medical cannabis program.

HHMM. “**Private entity**” means a private, non-profit organization that applies to become or is licensed as a producer and distributor of cannabis, concentrates or cannabis-derived products.

H NN. “**Proficiency testing**” means testing conducted by the department or its agent to determine the ability of a laboratory applicant or approved laboratory to accurately identify presence, quantity or other factors pertaining to a given analyte.

OO. “**Qualified patient**” means a resident of New Mexico who has been diagnosed by a practitioner as having a debilitating medical condition and has received a registry identification card issued pursuant to the requirements of the act or department rules.

**JPP.** “Registry identification card” means a document issued and owned by the department which identifies a qualified patient authorized to engage in the use of cannabis for a debilitating medical condition or a document issued by the department which identifies a primary caregiver authorized to engage in the intrastate possession and administration of cannabis for the sole use of the qualified patient.

**KKQQ.** “Representative” means an individual designated as the applicant’s or petitioner’s agent, guardian, surrogate, or other legally appointed or authorized health care decision maker pursuant to the Uniform Health Care Decisions Act, Sections 24-7A-1 et seq. (NMSA 2007).

**LLRR.** “Secretary” means the secretary of the New Mexico department of health.

**MMSS.** “Secure grounds” means a facility that provides a safe environment to avoid loss or theft.

**NNTT.** “Security alarm system” means any device or series of devices capable of alerting law enforcement, including, but not limited to, a signal system interconnected with a radio frequency method such as cellular, private radio signals, or other mechanical or electronic device used to detect and/or report an emergency or unauthorized intrusion.

**OOUU.** “Security policy” means the instruction manual or pamphlet adopted or developed by the licensed producer containing security policies, safety and security procedures, personal safety and crime prevention techniques.

**PPVV.** “Seedling” means a cannabis plant that has no flowers.

~~\_\_\_\_\_ QQ. “Submission date” means the date of submission of the last item in an application, petition or proposal.~~

~~\_\_\_\_\_ RRWW. “Segregate” means to separate and withhold from use or sale batches, lots, cannabis, usable cannabis or cannabis-derived products in order to first determine its suitability for use through testing by an approved laboratory.~~

~~\_\_\_\_\_ XX. “THC” means tetrahydrocannabinol, the primary psychoactive ingredient in cannabis.~~

~~\_\_\_\_\_ YY. “Technical evidence” means scientific, clinical, medical or other specialized testimony, or evidence, but does not include legal argument, general comments, or statements of policy or position concerning matters at issue in the hearing.~~

~~\_\_\_\_\_ SS. “Topical treatment” means a transcutaneous therapeutic cannabis extract formulation.~~

~~\_\_\_\_\_ TT ZZ. “Testing” means the process and procedures provided by an approved laboratory for testing of cannabis and cannabis derived products, consistent with provisions of this rule.~~

~~\_\_\_\_\_ AAA. “Unit” means a quantity of usable cannabis, concentrate or cannabis-derived product that is used in identifying the maximum supply that a qualified patient may possess for purposes of department rules.~~

~~\_\_\_\_\_ BBB. “Usable cannabis” means the dried leaves and flowers of the female cannabis plant and any mixture or preparation thereof cannabis-derived products, including ointments concentrates, but does not include the seedlings, seeds, stalks, or roots of the plant.~~

[7.34.3.7 NMAC - Rp, 7.34.3.7 NMAC, 12/30/2010/7/15/2014]

#### 7.34.3.8 QUALIFYING DEBILITATING MEDICAL CONDITIONS:

A. **Statutorily-approved conditions:** As of the date of promulgation of this rule, specific qualifying debilitating medical conditions, diseases and treatments (“qualifying conditions”) identified in the Lynn and Erin Compassionate Use Act [NMSA 1978, Section 26-2B-3(B)] include:

- (1) cancer;
- (2) glaucoma;
- (3) multiple sclerosis;
- (4) damage to the nervous tissue of the spinal cord, with objective neurological indication of intractable spasticity;
- (5) epilepsy;
- (6) positive status for human immunodeficiency virus or acquired immune deficiency syndrome; and
- (7) admission into hospice care in accordance with rules promulgated by the department.

B. **Department-approved conditions:** The department finds that the following additional qualifying conditions result in pain, suffering or debility for which there is credible evidence that the medical use of cannabis could be of benefit, through the alleviation of symptoms, and the department accordingly approves these conditions as qualifying debilitating medical conditions for the participation of a qualified patient or primary caregiver in the medical cannabis program. ~~Pursuant to this rule, a patient applying on the basis of having any qualifying condition must submit written certification from the patient’s practitioner which must attest (1) to the diagnosis of the medical condition; (2) that the condition is debilitating; (3) that standard treatments have failed to bring adequate relief; and (4) that potential risks and benefits of the use of medical cannabis for the condition have been discussed with the~~

~~patient (7.34.3.9 NMAC). A patient who applies on the basis of having a department-approved condition may further be required to satisfy additional eligibility criteria, as specified after each of the following department-approved conditions. The department-approved conditions include:~~

- (1) severe chronic pain:
  - (a) objective proof of the etiology of the severe chronic pain shall be included in the application; and
  - (b) two practitioners familiar with the patient's chronic pain shall provide written certification that the patient has an unremitting severe chronic pain condition; one certification shall be from a primary care provider; the second certification shall be from a specialist with expertise in pain management or a specialist with expertise in the disease process that is causing the pain;
- (2) painful peripheral neuropathy: application to the medical cannabis program shall be accompanied by medical records that confirm the objective presence of painful peripheral neuropathy that has been refractory to other treatments;
- (3) intractable nausea/vomiting;
- (4) severe anorexia/cachexia;
- (5) hepatitis C infection currently receiving antiviral treatment: the written certification shall attest:
  - (a) that the hepatitis C infection is currently being treated with antiviral drugs;
  - (b) to the anticipated duration of the hepatitis C antiviral treatment; and
  - ~~(c) that standard treatments for the management of side effects associated with hepatitis C treatment have failed to bring adequate relief;~~
- (6) Crohn's disease;
- (7) post-traumatic stress disorder (PTSD): each individual applying to the program for enrollment shall submit medical records that confirm the diagnosis of PTSD based upon the evaluation of a psychiatrist or psychiatric nurse practitioner and meeting the diagnostic criteria of the current *diagnostic and statistical manual of mental disorders*;
- (8) inflammatory autoimmune-~~mediate~~mediated arthritis: ~~each individual applying to the written certification program for enrollment shall come from~~ submit medical records that confirm the diagnosis of inflammatory autoimmune-mediated arthritis based upon the evaluation of a rheumatologist who is board-certified in rheumatology by the American board of internal medicine;
- (9) amyotrophic lateral sclerosis (Lou Gehrig's disease); and
- (10) inclusion body myositis;
- (11) spasmodic torticollis (cervical dystonia);
- (12) Parkinson's disease;
- (13) Huntington's disease; and
- (14) such other conditions as the secretary may approve.

~~CC. Additional application requirements for department-approved conditions: A patient applying on the basis of having a department-approved qualifying condition shall submit written certification from the patient's practitioner which shall attest:~~

- ~~(1) to the diagnosis of the medical condition;~~
- ~~(2) that the condition is debilitating;~~
- ~~(3) that standard treatments have failed to bring adequate relief; and~~
- ~~(4) that potential risks and benefits of the use of medical cannabis for the condition have been discussed with the patient, in accordance with this rule. A patient who applies on the basis of having a department-approved condition may also be required to satisfy additional eligibility criteria, as specified in this rule.~~

~~D. Modification or removal of department-approved conditions: The secretary may remove or modify a department-approved condition only if the secretary determines, on the basis of substantial credible medical and scientific evidence, and after an opportunity for review of the proposed removal or modification by the medical advisory board, that the use of cannabis by patients who have the approved condition would more likely than not result in substantial harm to the patients' health.~~

~~[7.34.3.8 NMAC - N, ~~12/30/2014~~7/15/2014]~~

~~7.34.3.9-~~

~~**7.34.3.9 QUANTITY OF USABLE CANNABIS THAT MAY BE POSSESSED BY A QUALIFIED PATIENT OR PRIMARY CAREGIVER:**~~

~~**A. Maximum quantity:** A qualified patient and a qualified patient's primary caregiver may collectively possess within any three-month period a quantity of usable cannabis no greater than one-hundred-and-~~

seventy (170) total units. For purposes of department rules, this quantity is deemed an adequate supply. A qualified patient and primary caregiver may also possess cannabis seeds.

**B. Calculation of units:** For purposes of department rules, one unit of usable cannabis shall consist of one (1) gram of the dried leaves and flowers of the female cannabis plant, or 0.2 grams (200 milligrams) of THC for cannabis-derived products.

**C. Maximum THC content of concentrates:** A qualified patient or primary caregiver shall not possess a concentrated cannabis-derived product that contains greater than sixty (60) percent THC by weight.

**D. Medical exception:** A greater quantity of usable cannabis, not to exceed eighty-five (85) additional units, may be allowed, or a concentrated cannabis-derived product with THC content greater than sixty (60) percent by weight may be allowed, at the department's discretion, upon the submission of a statement by a medical practitioner explaining why a greater number of units of usable cannabis, or a higher concentration of THC in concentrated cannabis-derived product, is medically necessary. Any such allowance shall be reviewed for approval by the program's medical director. A request for a greater concentration of THC in concentrated cannabis-derived product shall not be granted to a patient who has been granted a medical exception to possess additional units of usable cannabis.

[7.34.3.9 NMAC - N. 7/15/2014]

#### **7.34.3.10 QUALIFIED PATIENT AND PRIMARY CAREGIVER REGISTRY IDENTIFICATION CARD APPLICATION REQUIREMENTS:**

**A.** The department shall issue a registry identification card to an applicant for the purpose of participating in the medical cannabis program upon the written certification of the applicant's practitioner and supporting application documents. Certifications from certifying providers must be obtained within ninety (90) calendar days prior to the expiration of the patient's registry identification card.

**B.** The department may require the submittal of a recent photograph, fingerprints, and other biometric identifying information from a patient applicant and primary caregiver applicant.

**C. Patient and primary caregiver application fees:** A patient applicant or primary caregiver applicant shall submit with each initial application and renewal application for a registry identification card a fee of fifty dollars (\$50), or twenty five dollars (\$25) with a showing of Medicaid enrollment with the U.S. department of health and human services. A fifty dollar (\$50) payment is required for replacement of a lost or stolen registry identification card.

**D.** The following information shall be provided in (or as an attachment to) the participant enrollment form submitted to the department in order for a registry identification card to be obtained and processed.

**(1)** An attached original medical provider certification for patient eligibility form shall contain:

- (a)** the name, address and telephone number of the practitioner;
- (b)** the practitioner's clinical licensure;
- (c)** the patient applicant's name and date of birth;
- (d)** the medical justification for the practitioner's certification of the patient's debilitating

medical condition, which shall include but not be limited to a statement that, in the practitioner's professional opinion, the practitioner believes that the potential health benefits of the medical use of cannabis would likely outweigh health risks for the patient;

**(e)** an attestation that the practitioner's primary place of practice is located within the state of New Mexico;

- (f)** the practitioner's signature and the date;
- (g)** the name, address and date of birth of the applicant;
- (h)** the name, address and telephone number of the applicant's practitioner;
- (i)** a reasonable legible photocopy of the applicant's New Mexico driver's license or comparable state of New Mexico or federal issued photo identification card verifying New Mexico residence;
- (j)** documented parental consent, if applicable, to the applicant;
- (k)** the applicant's debilitating medical condition;
- (l)** the length of time the applicant has been under the care of the practitioner providing the

medical provider certification for patient eligibility;

- (m)** the applicant's signature and date; and
- (n)** a signed consent for release of medical information related to the patient's debilitating

medical condition, on a form provided by the medical cannabis program.

**BE. Qualified minor:** The department shall issue a registry identification card to an applicant under the age of eighteen (18) for the purpose of participating in the medical cannabis program upon the medical provider

certification for patient eligibility from the applicant's practitioner and supporting application documents required under this rule. The qualified minor parental consent form shall require the following information to be provided:

- (1) written documentation that the applicant's practitioner has explained the potential risks and benefits of the use of cannabis to both the applicant and parent or representative of the applicant; and
- (2) written consent of the applicant's parent or legal representative consents to:
  - (a) allow the applicant's use of cannabis and cannabis-derived products;
  - (b) serve as the applicant's primary caregiver; and
  - (c) control the acquisition of the cannabis, dosage and the frequency of the use of cannabis and cannabis-derived products by the applicant.

**CF. Primary caregiver:** The department shall issue a registry identification card to a primary caregiver applicant for the purpose of managing the well-being of up to four (4) qualified patients pursuant to the requirements of this rule upon the completion and approval of the primary caregiver application form available from the medical cannabis program. In order for a registry identification card to be obtained and processed, the following information shall be submitted to the medical cannabis program:

- (1) New Mexico driver's license or comparable state of New Mexico or federal issued photo identification card verifying that the applicant is at least eighteen (18) years of age and is a resident of New Mexico;
- (2) written approval by each qualified patient, and written approval by at least one certifying practitioner for each qualified patient, authorizing the primary caregiver's responsibility for managing the well-being of the patient(s) with respect to the medical use of cannabis;
- (3) the name(s), address(es), telephone number(s) and date of birth of the qualified patient(s);
- (4) the name, address and telephone number of each qualified patient's practitioner;
- (5) the name, address, and telephone number of the applicant primary caregiver;
- (6) an attestation from the primary caregiver applicant that he or she is a resident of the state of New Mexico;
- (7) the applicant primary caregiver's signature and the date; and
- (8) documentation of completed nationwide and statewide background checks conducted within six months of the application submission date.

**DG. Primary caregiver application requirements:** Criminal history screening requirements.

- (1) All primary caregiver applicants are required to consent to a nationwide and statewide DPS criminal history screening background check. All applicable application fees associated with the nationwide and statewide criminal history screening background check shall be paid by the primary caregiver applicant.
- (2) Individuals convicted of a felony violation of Section 30-31-20, 30-31-21, or 30-31-22 NMSA 1978, or a violation of any equivalent out-of-state statute in any jurisdiction, are prohibited from serving as a primary caregiver. If an applicant has been convicted of a felony violation of Section 30-31-1 et seq. NMSA 1978, other than Sections 30-31-20 through 30-31-22, and the final completion of the entirety of the associated sentence of such felony conviction has been less than three (3) years from the date of the applicant's application as a primary caregiver, then the applicant is prohibited from being a primary caregiver. The applicant and qualified patient shall be notified of his or her disqualification from being a primary caregiver. If the applicant has been convicted of more than one (1) felony violation of Section 30-31-1 et seq. NMSA 1978 or a violation of an equivalent out-of-state statute in any jurisdiction, the applicant and qualified patient shall be notified that the applicant is permanently prohibited from being a primary caregiver and cannot be issued a medical use cannabis registry identification card.

**EH. Primary caregiver requirements:**

- (1) A primary caregiver applicant shall be a resident of New Mexico.
- (2) A qualified patient's primary caregiver shall be permitted to obtain and transport medical cannabis from a licensed non-profit to the qualified patient.
- (3) The primary caregiver of a qualified patient who holds a personal production license may assist the qualified patient to produce medical cannabis at the designated licensed location, identified on the personal production license; the primary caregiver may not independently produce medical cannabis.
- (4) A qualified patient shall only reimburse their primary caregiver for the cost of travel, supplies or utilities associated with the possession of medical cannabis, or cannabis-derived products by the primary caregiver for the qualified patient. No other cost associated with the possession of medical use cannabis, or cannabis-derived products by the primary caregiver for the qualified patient, including the cost of labor, shall be reimbursed or paid. All medical cannabis, or cannabis-derived products possessed by a primary caregiver for a qualified patient isare the property of the qualified patient.

**F. (5)** A qualified patient shall notify the medical cannabis program in the event that the qualified patient ceases to retain the services of a primary caregiver. A primary caregiver shall promptly disenroll

from the medical cannabis program at the time that the primary caregiver's services are no longer used by a qualified patient in their care.

**I. Certifying practitioner requirements:**

(1) A patient may not be certified by a practitioner who is related to the patient within the second degree of consanguinity or the first degree of affinity, including a spouse, child, stepchild, parent, step-parent, sibling, grandparent, mother-in-law, father-in-law, son-in law, or daughter-in-law of the patient.

(2) A practitioner's primary place of practice must be located within the state of New Mexico in order for the practitioner to ~~a~~ certify a patient's eligibility.

~~(3)~~ **(3)** In order to certify a patient's application, a practitioner must have an actual physician-client relationship with the applicant or qualified patient, and shall conduct an in-person evaluation of the applicant or qualified patient prior to issuing a certification.

~~(4)~~ (4) A practitioner may be prohibited from certifying a patient's application for:

(a) failure to comply with any provision of this rule;

(b) falsification of any material or information submitted to the department;

(c) threatening or harming an employee of a producer, a medical practitioner, a patient, or an employee of the department; or

(d) any determination by the practitioner's licensing body that practitioner has engaged in unprofessional or dishonorable conduct.

[7.34.3.9 NMAC - Rp, 7.34.3.8 NMAC, ~~12/30/2014~~15/2014]

**7.34.3.1011 REGISTRY IDENTIFICATION CARDS:**

**A. Department inquiry:**

(1) The department may verify information on each application and accompanying documentation by the following methods:

(a) contacting each applicant by telephone or mail, or if proof of identity is uncertain, ~~the department~~ by requiring a face-to-face meeting and the production of additional identification materials;

(b) when applicable, contacting a minor's parent or legal representative;

(c) contacting the New Mexico medical board, the New Mexico board of nursing, board of pharmacy, or other licensing agencies to verify that the practitioner is licensed to practice and prescribe controlled substances in New Mexico and is in good standing; and

(d) contacting the practitioner to obtain further documentation to verify that the applicant's medical diagnosis and medical condition qualify the applicant for enrollment in the medical ~~use~~ cannabis program.

(2) The department shall approve or deny an application within thirty (30) calendar days of receipt of the completed application. A request by the department for additional information shall toll this period until such time as the requested information is received.

**B. Department registry identification card:** The department shall issue a registry identification card within five (5) business days of approving an application. A registry identification card shall ~~contain~~ include the name, ~~address and address and~~ date of birth of the qualified patient and primary caregiver (if any), the date of issuance and expiration date of the registry identification card, and a code maintained by the ~~division~~ program which identifies the qualified patient or primary caregiver. Unless renewed at an earlier date, suspended or revoked, a registry identification card shall be valid for a period of one (1) year from the date of issuance and shall expire at midnight on the day indicated on the registry identification card as the expiration date. A registry identification card is the property of the department, and shall be returned to the department upon the disenrollment, suspension, or revocation of a qualified patient or primary caregiver, and upon a change of address, or change of a qualified patient's primary caregiver.

**C. Supplemental information requirement:** A qualified patient or primary caregiver who possesses a registry identification card shall notify the department of any change in the person's name, address, qualified patient's primary caregiver, or change in status of the qualified patient's debilitating medical condition, within ten (10) calendar days of the change. ~~An extension shall be granted by the medical cannabis program manager or designee upon the showing of good cause.~~ Failure to provide notification of any change ~~shall~~ may result in the immediate revocation of the registry identification card and all lawful privileges provided under the act.

**D. Registry identification card application denial:** The medical director or designee shall deny an initial application if the application fails to satisfy any requirement of this rule, if the applicant fails to provide the information required, if the department determines that the information provided is false, if the patient does not have a debilitating medical condition eligible for enrollment in the program as determined by the medical director, or if the applicant's certifying provider(s) or other medical provider identified in the application or supporting

documentation, determine(s) that the use of cannabis by the patient would more likely than not be detrimental to the patient's health. The medical director or designee may also deny an application if the applicant has threatened or harmed an employee of a producer, a medical practitioner, a patient, or an employee of the department. A person whose application has been denied shall not reapply for six (6) months from the date of the denial, unless otherwise authorized by the department, and is prohibited from all lawful privileges provided by this rule and act. A person whose application as a qualified patient or primary caregiver has been denied for failure to complete an application or failure to meet a submittal requirement of this rule may request a record review to be conducted by the medical cannabis program.

**E. Registry identification card renewal application:** Each registry identification card issued by the department is valid for one (1) year from the date of issuance. A qualified patient or primary caregiver shall apply for a registry identification card renewal no less than thirty (30) calendar days prior to the expiration date of the existing registry identification card in order to prevent interruption of possession of a valid (unexpired) registry identification card. Certifications from certifying providers must be obtained within ninety (90) calendar days prior to the expiration of the patient's registry identification card.

**F. Non-transferable registration of registry identification card:** A registry identification card shall not be transferred by assignment or otherwise to other persons. Any attempt shall result in the immediate revocation of the registry identification card and all lawful privileges provided by this rule and act.

**G. Automatic expiration of registry identification card by administrative withdrawal:** Upon request of the qualified patient or primary caregiver, the qualified patient or primary caregiver may discontinue the medical cannabis program by an administrative withdrawal. A qualified patient or primary caregiver that intends to seek an administrative withdrawal shall notify the licensing authority no later than thirty (30) calendar days prior to withdrawal and return the proof of registry identification to the program.

**H. Lost or stolen registry identification card:** The qualified patient or primary caregiver shall report a lost or stolen registry identification card to the medical cannabis program within five (5) business days after discovery. An extension shall be granted upon notification and receipt of the Information Change or Card Replacement Form provided by the medical cannabis program manager upon the showing of good cause. Upon notification, and remittance of the fifty dollar (\$50) replacement fee, the medical cannabis program manager or designee shall issue a new registry identification card. The patient or primary caregiver shall verify the accuracy of all documentation in the most recent application. Unless documentation in the most recent application has changed, the qualified patient or primary caregiver shall not be required to submit a new application.

[7.34.3.10 NMAC - Rp, 7.34.3.9 NMAC, 12/30/2010/7/15/2014]

#### **7.34.3.11 DENIAL OF POSSESSION OF AN INITIAL PATIENT OR PRIMARY CAREGIVER APPLICATION USABLE CANNABIS:**

~~**A. Administrative review:** All patient applicants or primary caregivers whose initial application for a registry identification card has been denied may request a record review from the department.~~

~~**B. Procedure for requesting informal administrative review:**~~

~~(1) An applicant given notice of an application denial may submit a written request for an administrative review. To be effective, the written request shall:~~

~~(a) be made within thirty (30) calendar days, as determined by the postmark, from the date of the denial notice issued by the department;~~

~~(b) be properly addressed to the medical cannabis program;~~

~~(c) state the applicant's name, address, and telephone numbers;~~

~~(d) state the applicant's proposed status as A qualified patient or primary caregiver;~~

~~(e) if the applicant is a potential primary caregiver, state the anticipated date of which service shall commence;~~

~~(f) provide a brief narrative rebutting the circumstances of the application denial, and~~

~~(g) if applicable, provide supplemental documentation from the applicant's practitioner supporting the debilitating medical condition as eligible for the program.~~

~~(2) If the applicant wishes to submit additional documentation for consideration, such additional documentation must be included with the request for an administrative review.~~

~~**C. Administrative review proceeding:** The administrative review proceeding shall be a closed proceeding shall ensure that is limited to an administrative review of written application materials and documents offered to verify eligibility. The administrative review proceeding is not an adjudicatory hearing, and an individual whose initial application for a registry identification card has been denied shall not be entitled to an adjudicatory hearing to contest the denial. The administrative review shall be conducted by the administrative review committee.~~

~~In cases where the administrative review committee finds the need for additional or clarifying information, the review committee shall request that the applicant supply such additional information within the time set forth in the committee's request that all cannabis, cannabis-derived products and paraphernalia are kept secure and out of reach of children.~~

~~**D. Final determination:**~~

~~(1) Content. The administrative review committee shall render a written decision setting forth the reasons for the decision and the evidence upon which the decision is based.~~

~~(2) Effect. The decision of the administrative review committee is the final decision of the informal administrative review proceeding.~~

~~(3) Notice. A copy of the decision shall be mailed to the applicant.~~

~~**E. Judicial review:** Except as otherwise provided by law, there shall be no right to judicial review of a decision by the administrative review committee.~~

~~[7.34.3.11] **B.** A qualified patient and primary caregiver shall ensure that all cannabis and cannabis-derived products that are purchased from a licensed non-profit producer remain in the package or container provided by the non-profit entity when not in use. If the package or container is damaged, the product label and any other identifying information from the package or container shall be kept and remain with the cannabis or cannabis-derived product upon transfer to another package or container.~~

~~[7.34.3.12 NMAC - RPN, 7.34.3.10 NMAC, 12/30/2010/15/2014]~~

**7.34.3.1213 MONITORING AND CORRECTIVE ACTIONS:**

**A. Monitoring:**

(1) The department or its designee may perform on-site assessments of a qualified patient or primary caregiver to determine compliance with these rules. The department may enter the premises of a qualified patient or primary caregiver during business hours for purposes of monitoring and compliance. Twenty-four (24) hours' notice will be provided to the qualified patient or primary caregiver prior to an on-site assessment except when the department has a reasonable suspicion to believe that providing notice will result in the destruction of evidence or that providing such notice will impede the department's ability to enforce these regulations.

(2) All qualified patients or primary caregivers shall provide the department or the department's designee immediate access to any material and information necessary for determining compliance with these requirements.

(3) Failure by the qualified patient or primary caregiver to provide the department access to the premises or information may result in the revocation of the qualified patient or primary caregiver enrollment and referral to state law enforcement.

(4) Any failure by a qualified patient or primary caregiver to adhere to these rules may result in sanction(s), including suspension, revocation, non-renewal or denial of license registration and referral to state or local law enforcement.

(5) The department may refer complaints involving alleged criminal activity made against a qualified patient or primary caregiver to the appropriate New Mexico state or local authorities.

**B. Corrective action:**

(1) If violations of these requirements are cited as a result of a monitoring visit, the qualified patient or primary caregiver shall be provided with an official written report of the findings within seven (7) business days following the monitoring visit.

(2) Unless otherwise specified by the department, the qualified patient or primary caregiver shall correct the violation within five (5) calendar days of receipt of the official written report citing the violation(s).

(3) The violation shall not be deemed corrected until the department verifies in writing within seven (7) calendar days of receiving notice of the corrective action that the corrective action is satisfactory.

(4) If the violation has not been corrected, the program manager or designee may issue a notice of contemplated action to revoke the enrollment of the qualified patient.

**C. Suspension of enrollment without prior hearing:** If immediate action is required to protect the health and safety of the general public, the qualified patient or primary caregivers, the medical cannabis program manager or designee may suspend the qualified patient or primary caregiver's enrollment in the medical cannabis program without notice.

~~(1) A qualified patient or primary caregiver whose enrollment has been summarily suspended is entitled to an administrative review not later than thirty (30) calendar days after the enrollment is summarily suspended.~~

- ~~(2) An administrative review requested subsequent to a summary suspension shall be conducted by the administrative review committee.~~
  - ~~(3) The administrative review committee shall conduct the administrative review on the summary suspension by reviewing all documents submitted by both the participant and the department.~~
  - ~~(4) The administrative review is not an adjudicatory hearing; rather, the sole issue in an administrative review of a summary suspension is whether the individual's enrollment shall remain suspended pending a final administrative adjudicatory hearing and decision.~~
  - ~~(5) An enrollee given notice of summary suspension by the medical cannabis program may submit a written request for an administrative review. To be effective, the written request shall:~~
    - ~~(a) be made within thirty (30) calendar days, as determined by the postmark, from the date of the notice issued by the department;~~
    - ~~(b) be properly addressed to the medical cannabis program;~~
    - ~~(c) state the requestor's name, address, and telephone numbers;~~
    - ~~(d) provide a brief narrative rebutting the circumstances of the suspension; and~~
    - ~~(e) be accompanied by any additional documentation offered in support of the request.~~
- [7.34.3.1211 NMAC - Rp, 7.34.3.1113 NMAC, 12/30/2010]

7/15/2014]

**7.34.3.1314 PROHIBITIONS, RESTRICTIONS AND LIMITATIONS ON THE USE OF CANNABIS BY QUALIFIED PATIENTS:** Participation in the medical cannabis program by a qualified patient or primary caregiver does not relieve the qualified patient or primary caregiver from:

- ~~A. criminal prosecution or civil penalties for activities not authorized in this rule and act;~~
- ~~B. B. criminal prosecution or civil penalties for fraudulent representation to a law enforcement officer about the person's participation in the program to avoid arrest or prosecution;~~
- ~~C. liability for damages or criminal prosecution arising out of the operation of a vehicle while under the influence of cannabis, or cannabis-derived products; or~~
- ~~D. criminal prosecution or civil penalty for possession, distribution or transfers of cannabis, transfer, or use of cannabis or a cannabis-derived product:~~
  - ~~(1) in a school bus or public vehicle;~~
  - ~~(2) on school grounds or property;~~
  - ~~(3) in the workplace of the qualified patient's or primary caregiver's employment;~~
  - ~~(4) at a public park, recreation center, youth center or other public place;~~
  - ~~(5) to a person not approved by the department pursuant to this rule;~~
  - ~~(6) outside New Mexico or attempts to obtain or transport cannabis, or cannabis-derived products from outside New Mexico; or~~
  - ~~(7) that exceeds the allotted amount of useable/usable medical use cannabis, or cannabis-derived products.~~

[7.34.3.1314 NMAC - N, 12/30/2010/7/15/2014]

**7.34.3.14 SUMMARY SUSPENSION, REVOCATION,15 DISCIPLINARY ACTIONS AND APPEAL PROCESS:**

- ~~A. **Suspension or Grounds for disciplinary action:** Disciplinary action may be taken against a qualified patient, patient-applicant, primary caregiver or primary caregiver-applicant. Disciplinary action may include revocation of registry identification card: Violation of any provision of this rule may result in either the, suspension, or denial, summary suspension of a qualified patient's or primary caregiver's registry identification card or issuance of a notice of contemplated action by the medical cannabis program manager or designee to suspend or revoke the qualified patient's or primary caregiver's registry identification card, and the, summary revocation of all lawful privileges under the Lynn and Erin Compassionate Use Act, NMSA 1978, Section 26-2B-1 et seq.~~
- ~~B. **Grounds for revocation or suspension of enrollment or denial of renewal application:** A patient or primary caregiver's registry identification card may be revoked or suspended and a renewal application, and other action, Disciplinary action may be denied/imposed for:~~
  - ~~(1) failure to comply with or satisfy any provision of this rule;~~
  - ~~(2) falsification or misrepresentation of any material or information submitted to the department;~~
  - ~~(3) failure/failing to allow inspection and/or impeding a monitoring visit by an authorized representative/representatives of the department;~~

~~(4) any instance of failure to adhere to any acknowledgement, verification or other representation made to the department;~~

~~(5) failure to submit or disclose information required by this rule or otherwise requested by the department;~~

~~(6) failure to correct any violation of this rule cited as a result of a monitoring visit;~~

~~(7) diversion of cannabis or a cannabis-derived product, as determined by the department;~~

~~(8) threatening or harming an employee of a producer/patient, a medical practitioner, a patient, or an employee of the department;~~

~~(9) for primary caregivers: any determination by the primary caregiver's licensing body that the primary caregiver has engaged in unprofessional or dishonorable conduct;~~

~~(10) for primary caregivers: conviction of the primary caregiver of any of the disqualifying convictions identified by department rule;~~

~~(11) for patients: failure of the patient to satisfy any criterion identified as a prerequisite to eligibility for a condition approved by the department; or~~

~~(12) for patients: if a certifying medical provider of the patient determines that the use of cannabis by the patient would more likely than not be detrimental to the patient's health; and~~

~~C (13) any other basis identified in this rule.~~

**B. Request for hearing:** A qualified patient or primary caregiver ~~whose enrollment has been summarily suspended, or who is the subject of disciplinary action, or an applicant~~ who has received a notice of contemplated action to ~~suspend or revoke~~ deny their enrollment/application for any reason other than failure to submit a completed application or failure to meet a submittal requirement of this rule, may request a hearing in writing, ~~in addition to a request for a record review, for the purpose of review of such action.~~ The appellant shall file the request for hearing within thirty (30) calendar days of the date the action is taken or the notice of contemplated action is received. The request shall:

(1) be properly addressed to the medical cannabis program;

(2) state the requestor's name, address, and telephone numbers; ~~include a statement of the facts relevant to the review of the action; and~~

(3) include a statement of the ~~provision of the act and the rules promulgated under the act that are relevant to the review of the action;~~

~~(4) include a statement of the arguments/issues that the appellant considers relevant to the review of the action; and~~

~~(5) include any other relevant evidence.~~

~~D~~ **C. Hearing process:**

(1) All formal adjudicatory hearings held pursuant to this regulation shall be conducted by a hearing examiner appointed by the secretary.

(2) Hearings shall be conducted in Santa Fe, New Mexico, or, with the consent of the parties, at another location.

(3) Due to federal and state laws regarding the confidentiality of protected health information, all hearings held pursuant to this section shall be closed to the public.

(4) The hearing shall be recorded on audiotape or other means of sound reproduction.

(5) Any hearing provided for in this rule may be held telephonically, ~~with the consent of the parties.~~

**ED. Scheduling:** The department shall schedule and hold the hearing no later than sixty (60) calendar days from the date the department receives the appellant's request for hearing. The hearing examiner may extend the sixty (60) day time period for good cause shown, or the parties may extend that period by mutual agreement. The department shall issue notice of the hearing, which shall include:

(1) a statement of the time, place and nature of the hearing;

(2) a statement of the legal authority and jurisdiction under which the hearing is to be held; ~~and~~

(3) a short and plain statement of the ~~matters/subject of fact and law asserted; and~~

~~(4) all necessary telephone numbers if a telephonic hearing shall be conducted.~~

**FE. Presentation of evidence:** All parties shall be given the opportunity to respond and present evidence and argument on ~~all~~ relevant issues.

**GF. Record of proceeding:** The record of the proceeding shall include the following:

(1) all pleadings, motions and ~~intermediate~~ rulings;

(2) evidence and briefs received or considered;

(3) a statement of ~~any~~ matters officially noticed;

(4) offers of proof, objections and rulings thereon;

- (5) proposed findings and conclusions; and
- (6) any action recommended by the hearing examiner.

~~H. **Transcription of the proceedings:** A party requesting a transcript shall bear the cost of transcription, to include any duplication costs.~~

~~I. **G. Audio recording:** A party may request a copy of the audio recording of the proceedings.~~

**H. Procedures and evidence:**

- (1) ~~Any~~ party may be represented by a person licensed to practice law in New Mexico or a non-lawyer representative, or may represent himself or herself.
- (2) The rules of evidence as applied in the courts of law shall do not apply in these proceedings. Any relevant evidence may shall be admitted. Irrelevant, immaterial or unduly repetitious evidence may be excluded.
- ~~(3) Documentary and other physical evidence shall be authenticated or identified by any reasonable means that shows that the matter in question is what the proponent claims it to be.~~
- ~~(4)~~ (3) The experience, technical competence and specialized knowledge of the hearing examiner, the department or the department's staff may be used in the evaluation of evidence.
- (5) An appellant's failure to appear at the hearing at the date and time noticed for the hearing shall constitute a default.

**II. Conduct of proceeding:** Unless the hearing examiner determines a different procedure to be appropriate, the hearing shall be conducted as follows:

- (1) the appellant may present an opening statement ~~on the merits~~ and the ~~appellee~~ department may ~~make a present an opening~~ statement ~~of the defense~~ or reserve the statement until presentation of ~~that party's~~ case;
- (2) upon conclusion of any opening statements, the appellant shall present his or her case ~~in chief~~;
- (3) upon the conclusion of the appellant's case ~~in chief~~, the department shall present its case ~~in defense~~;
- (4) upon conclusion of ~~the department's~~ ~~either party's~~ case ~~in chief~~, the ~~appellant~~ ~~opposing party~~ may present rebuttal ~~argument; evidence; and~~
- (5) ~~upon conclusion after presentation~~ of the parties' cases ~~in chief and rebuttal arguments (if any); evidence by the parties~~, the parties may present closing arguments; ~~and~~
- ~~(6) thereafter, the matter shall be considered submitted for recommendation by the hearing examiner.~~

~~K. J. **Burden of proof:** The appellant bears the burden of establishing by a preponderance of the evidence that the decision made or proposed by the department should be reversed or modified.~~

~~L. K. **Continuances:** The hearing examiner may grant a continuance for good cause shown. A motion to continue a hearing shall be made at least ten (10) calendar days before the hearing date.~~

**ML. Telephonic hearings:**

- (1) Any party requesting a telephonic hearing shall do so ~~within no less than~~ ten (10) business days ~~of prior to~~ the date of the ~~notice of the hearing~~. Notice of the telephonic hearing shall be ~~made given~~ to all parties and shall include all necessary telephone numbers.
- (2) Failure of an appellant to provide their correct telephone number or failure to be available at the commencement of the hearing shall be treated as a failure to appear and shall constitute a default.
- (3) The in-person presence of some parties or witnesses at the hearing shall not prevent the participation of other parties or witnesses by telephone with prior approval of the hearing examiner.

**NM. Recommended action and final decision:**

- (1) The parties may submit briefs including findings of fact and conclusions of law for consideration by the hearing examiner.
- (2) No ~~more later~~ than thirty (30) calendar days after the last submission by a party, the hearing examiner shall prepare and submit to the secretary a written ~~decision containing a~~ recommendation of action to be taken by the secretary. The recommendation shall propose sustaining, reversing, or modifying the proposed action of the department.
- (3) The secretary shall ~~accept, reject~~ issue a final written decision accepting or modify/rejecting the hearing examiner's recommendation in whole or in part no later than thirty (30) calendar days after receipt of the hearing examiner's recommendation. The final decision ~~or order shall be issued in writing and shall include a statement of findings and conclusions, and~~ shall identify the final action ~~to be~~ taken. Service of the secretary's final decision shall be made upon the appellant by registered or certified mail.

(4) The final decision or order shall be made a part of the patient or primary caregiver's file with the medical cannabis program.

[7.34.3.1415 NMAC - Rp, 7.34.3.1215 NMAC, 12/30/20107/15/2014]

**7.34.3.4516 EXEMPTION FROM STATE CRIMINAL AND CIVIL PENALTIES FOR THE MEDICAL USE OF CANNABIS:**

**A.** Possession of, or application for, a registry identification card shall not constitute probable cause or give rise to reasonable suspicion for any governmental agency to search the person or property of the person possessing or applying for the card.

**AB.** A qualified patient shall not be subject to arrest, prosecution or penalty in any manner by the state of New Mexico or a political subdivision thereof for the possession of or the use of medical cannabis if the quantity of cannabis, concentrates, or cannabis-derived products does not exceed an adequate supply as defined by rule.

**BC.** A primary caregiver shall not be subject to arrest, prosecution or penalty in any manner for the possession of cannabis by the state of New Mexico, or a political subdivision thereof, for the medical use by the qualified patient if the quantity of cannabis, concentrates, or cannabis-derived products does not exceed an adequate supply as defined by rule.

**CD.** A qualified patient or a primary caregiver shall be granted the full legal protections provided under the Lynn and Erin Compassionate Use Act, NMSA 1978, Section 26-2B-1 *et seq.*, by the state of New Mexico if the qualified patient or primary caregiver is in possession of a valid registry identification card. If the qualified patient or primary caregiver is not in possession of a valid registry identification card, the qualified patient or primary caregiver shall be given an opportunity to produce the registry identification card before any arrest or criminal charges or other penalties are initiated.

**DE.** A practitioner shall not be subject to arrest or prosecution, penalized in any manner or denied any right or privilege by the state of New Mexico, or political subdivision thereof, for recommending the medical use of cannabis or providing written certification for the medical use of cannabis pursuant to this rule and the act.

**EF.** Any property interest that is possessed, owned or used in connection with the medical use of cannabis, or acts incidental to such use, shall not be harmed, neglected, injured or destroyed while in the possession of New Mexico state or local law enforcement officials. Any such property interest shall not be forfeited under any New Mexico state or local law providing for the forfeiture of property except as provided in the Forfeiture Act.

Cannabis, cannabis-derived products, paraphernalia or other property seized from a qualified patient or primary caregiver in connection with the claimed medical use of cannabis shall be returned immediately upon the determination by a court or prosecutor that the qualified patient or primary caregiver is entitled to the protections of the provisions of this rule and the act, as may be evidenced by a failure to actively investigate the case, a decision not to prosecute, the dismissal of charges or acquittal.

**FG.** A person shall not be subject to arrest or prosecution by the state of New Mexico, or political subdivision thereof, for a cannabis-related offense for being in the presence of the medical use of cannabis as permitted under the provisions of this rule and the act.

[7.34.3.4516 NMAC - Rp, 7.34.3.4316 NMAC, 12/30/20107/15/2014]

**7.34.3.4617 QUALIFIED PATIENT, PRIMARY CAREGIVER, AND CERTIFYING MEDICAL PROVIDER CONFIDENTIALITY:** The department shall maintain a confidential file containing the names and contact information of the persons who have either applied for or received a registry identification card, as well as the names and contact information of certifying and diagnosing providers.

**A. Patient applicants and qualified patients:** Names and contact information regarding a qualified patient or patient-applicant shall be confidential and shall not be subject to disclosure, except:

(1) to employees or agents of the department as necessary to perform the duties of the department pursuant to the provisions of this rule and the act;

(2) to employees of New Mexico state or local law enforcement agencies, for the purpose of verifying that a person is lawfully enrolled in the medical cannabis program, or in the event that the medical cannabis program manager or designee has reason to believe that a qualified patient or patient-applicant may have violated an applicable law; and

(3) as provided in the federal Health Insurance Portability and Accountability Act (HIPAA) of 1996 and applicable state and federal regulations.

**B. Primary caregivers and certifying providers:** Names and contact information regarding a primary caregiver or certifying medical provider shall be confidential and shall not be subject to disclosure, except:

(1) to applicable licensing bodies, for the purpose of verifying the practitioner's licensure status, or in the event that the medical cannabis program manager or designee has reason to believe that a practitioner may have violated licensing requirements or an applicable law;

(2) to employees of New Mexico state or local law enforcement agencies, in the event that the medical cannabis program manager or designee has reason to believe that a primary caregiver or ~~certifying medical~~ provider may have violated an applicable law;

(3) as provided in the federal Health Insurance Portability and Accountability Act (HIPAA) of 1996 and applicable state and federal regulations.

[7.34.3.16 NMAC - Rp, 7.34.3.~~14~~<sup>17</sup> NMAC, ~~12/30/2010~~<sup>7/15/2014</sup>]

**7.34.3.~~17~~<sup>18</sup> DISPOSAL OF UNUSED CANNABIS:** Unused cannabis, ~~concentrate or cannabis-derived product~~ in the possession of ~~the~~ qualified patient or ~~primary~~ caregiver that is no longer needed for the patient's needs may be disposed of by transporting the unused portion to a state or local law enforcement office, or by destroying the unused cannabis. ~~Donation or sale to a qualified patient, primary caregiver or non-profit entity is prohibited.~~

[7.34.3.17 NMAC - Rp, 7.34.3.~~15~~<sup>18</sup> NMAC, ~~12/30/2010~~<sup>7/15/2014</sup>]

~~7.34.3.18 ASSESSMENT REPORT: The department shall evaluate the implementation of the Lynn and Erin Compassionate Use Act and regulations issued pursuant to that act and provide a report to the secretary of the department within one year of the effective date of these regulations. In performing its evaluation, the department shall focus on whether the needs of qualified patients are being met by the department's administration of the act and whether there is a demonstrable need for a state run production and distribution facility. The department's assessment report shall be issued every two years, shall be a public document, and shall contain de-identified data upon which the assessment is based.~~

~~[7.34.3.18~~

~~7.34.3.19 PROGRAM COOPERATION WITH LAW ENFORCEMENT:~~

~~A. The medical cannabis program shall be accessible via telephone 24-hours per day for state and local law enforcement to contact the program to determine the enrollment status of a patient, consistent with this rule, and shall make available a telephone number for this purpose. State and local law enforcement may obtain this telephone number by contacting the medical cannabis program's main number, or by visiting the medical cannabis program website.~~

~~B. The medical cannabis program shall cooperate with state and local law enforcement to provide education and training regarding the Lynn and Erin Compassionate Use Act and department rules.~~

~~[7.34.3.19 NMAC - Rp, N. 7/15/2014]~~

~~7.34.3.16 NMAC, 12/30/2010]~~

**7.34.3.1920 SEVERABILITY:** If any part or application of these rules is held to be invalid, the remainder or its application to other situations or persons shall not be affected. Failure to promulgate rules or implement any provision of these rules shall not interfere with the remaining protections provided by these rules and the act.

[7.34.3.19 NMAC - Rp, 7.34.3.~~17~~<sup>20</sup> NMAC, ~~12/30/2010~~<sup>7/15/2014</sup>]

#### **HISTORY OF 7.34.3 NMAC:**

##### **History of Repealed Material:**

7.34.3 NMAC, Registry Identification Cards (filed 12/01/2008) repealed ~~12/30/2010~~<sup>7/15/2014</sup>.

##### **NMAC History:**

7.34.3 NMAC, Registry Identification Cards (filed 12/01/2008) was and replaced by 7.34.3 NMAC, Registry Identification Cards, effective ~~12/30/2010~~<sup>7/15/2014</sup>.

**TITLE 7 HEALTH**  
**CHAPTER 34 MEDICAL USE OF CANNABIS**  
**PART 4 LICENSING REQUIREMENTS FOR PRODUCERS, PRODUCTION FACILITIES AND DISTRIBUTION**

**7.34.4.1 ISSUING AGENCY:** New Mexico Department of Health, ~~Public Health Division~~Medical Cannabis Program.

[7.34.4.1 NMAC - Rp, 7.34.4.1 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.4.2 SCOPE:** This rule applies to all licensed producers of medical use cannabis, defined in Section 26-2B-3 (D) NMSA 1978 as “any person or association of persons within New Mexico that the department determines to be qualified to produce, possess, distribute and dispense cannabis pursuant to the Lynn and Erin Compassionate Use Act and that is licensed by the department.” ~~All requirements contained herein are necessary prerequisites to the state’s ability to distinguish between authorized use under this act and unauthorized use under the state’s criminal laws.~~

[7.34.4.2 NMAC - Rp, 7.34.4.2 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.4.3 STATUTORY AUTHORITY:** The requirements set forth herein are promulgated by the secretary of the department of health; pursuant to the ~~general~~ authority granted under Section 9-7-6 (E) NMSA 1978, ~~as amended, and the authority granted under Sections 24-1-2(D), 24-1-3(I) and 24-1-5, NMSA 1978, of the Public Health Act, as amended, Section 53-8-1 et seq. NMSA 1978, and the Lynn and Erin Compassionate Use Act., 26-2B-1 et seq. NMSA 1978.~~ Although federal law currently prohibits any use of cannabis, the laws of ~~Alaska, California, Colorado, the District of Columbia, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, Oregon, Rhode Island, Vermont, and Washington~~several states permit the medical use and cultivation of cannabis. New Mexico joins this effort to provide for the health and welfare of its citizens. New Mexico adopts these regulations to accomplish the purpose of the Lynn and Erin Compassionate Use Act as stated in Section 26-2B-2, NMSA 1978, “to allow for the beneficial use of medical cannabis in a regulated system for alleviating symptoms caused by debilitating medical conditions and their medical treatments,” while at the same time ensuring proper enforcement of any criminal laws for behavior that has been deemed illicit by the state.

[7.34.4.3 NMAC - Rp, 7.34.4.3 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.4.4 DURATION:** Permanent.

[7.34.4.4 NMAC - Rp, 7.34.4.4 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.4.5 EFFECTIVE DATE:** ~~December 30, 2010,~~ July 1, 2014 unless a later date is cited at the end of a section.

[7.34.4.5 NMAC - Rp, 7.34.4.5 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.4.6 OBJECTIVE:** Ensuring the safe production, distribution and ~~dispensing~~dispensation of cannabis for the sole purpose of medical use for alleviating symptoms caused by debilitating medical conditions in a regulated system.

[7.34.4.6 NMAC - Rp, 7.34.4.6 NMAC, ~~12/30/2010~~7/15/2014]

**7.34.4.7 DEFINITIONS:**

**A.** “Act” means the Lynn and Erin Compassionate Use Act, NMSA 1978, Sections 26-2B-1 through 26-2B-7.

**B.** ~~“Administrative review committee” means an intra-department committee that reviews qualified patient or primary caregiver application denials, licensed producer denials, or the imposition of a summary suspension. The administrative review committee shall consist of the medical director for the department’s public health division (or that person’s designee); the director of the public health division (or that person’s designee); and the chief of the infectious disease bureau of the department’s public health division (or that person’s designee).~~

~~\_\_\_\_\_~~ **C.** ~~“Administrative withdrawal” means the procedure for the voluntary withdrawal of a qualified patient or primary caregiver from the medical cannabis program.~~

~~D.C.~~ **“Adequate supply”** means an amount of cannabis, derived solely from an intrastate and licensed source and in a form approved by the department, that is possessed by a qualified patient or collectively possessed by a qualified patient and the qualified patient’s primary caregiver, that is determined by the department to be no more than reasonably necessary to ensure the uninterrupted availability of cannabis for a period of three (3) months: An adequate supply shall not exceed six (6) ounces of useable cannabis, and with a personal production license only, four (4) mature plants and twelve (12) seedlings, or a three (3) month supply of topical treatment. A qualified patient and primary caregiver may also possess cannabis seeds, or ninety (90) consecutive calendar days.

~~E.~~ **“Adverse action”** includes the denial of any application, immediate revocation of the qualified patient or primary caregiver’s registry identification card, licensed producer revocation, referral to state or local law enforcement and loss of all lawful privileges under the act.

~~F.~~ **D. “Advisory board”** means the medical cannabis advisory board consisting of eight (8) practitioners representing the fields of neurology, pain management, medical oncology, psychiatry, infectious disease, family medicine and gynecology.

~~GE.~~ **“Applicant”** means any person applying to participate for enrollment or re-enrollment in the medical use of cannabis program as a qualified patient, primary caregiver or licensed producer.

~~F.~~ **“Approved laboratory”** means a laboratory that has been approved by the department specifically for the testing of cannabis, concentrates and cannabis derived products.

~~G.~~ **“Batch”** means, with regard to usable cannabis, a homogenous, identified quantity of cannabis harvested during a specified time period from a specified cultivation area, and with regard to concentrated and cannabis-derived product, means an identified quantity that is uniform, that is intended to meet specifications for identity, strength and composition, and that is manufactured, packaged and labeled during a specified time period according to a single manufacturing, packaging, and labeling protocol.

~~H.~~ **“Cannabis”** means all parts of the plant cannabis sativa and cannabis indica, whether growing or not; and the resin extracted from any part of the plant, and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its resin.

~~I.~~ ~~“Consent to release of medical information form”~~ **“Cannabis-derived product”** means a signed product, other than cannabis itself, which contains or is derived from cannabis, not including hemp.

~~J.~~ **“Concentrated cannabis-derived product (“concentrate”)** means a cannabis-derived product that is manufactured by a mechanical or chemical process that separates any cannabinoid from the cannabis plant, and that contains no less than thirty-percent (30%) THC by weight.

~~K.~~ **“Courier”** means a person or entity that transports usable cannabis within the state of New Mexico from a licensed non-profit producer to a qualified patient or primary caregiver ~~authorization form to release specific medical information relating to the use of cannabis.~~

~~JL.~~ **“Debilitating medical condition”** means:

- (1) cancer;
- (2) glaucoma;
- (3) multiple sclerosis;
- (4) damage to the nervous tissue of the spinal cord, with objective neurological indication of intractable spasticity;
- (5) epilepsy;
- (6) positive status for human immunodeficiency virus or acquired immune deficiency syndrome;
- (7) admission into hospice care in accordance with rules promulgated by the department; or
- (8) any other medical condition, medical treatment or disease as approved by the department which results in pain, suffering or debility for which there is credible evidence that medical use cannabis could be of benefit.

~~K.~~ **“Deficiency”** means a violation of or failure to comply with a provision of these requirements.

~~L.~~ **M. “Department”** means the department of health or its agent.

~~M.~~ **“Division”** means the public health division of the department of health.

~~N.~~ **“Facility”** means any building, space or grounds licensed for the production, possession ~~and,~~ testing, manufacturing or distribution of cannabis in any form, concentrates or cannabis-derived products.

~~O.~~ **“Intrastate”** means existing or occurring within the state boundaries of New Mexico.

~~P.~~ **P. “Laboratory applicant”** means a laboratory that seeks to become an approved laboratory, or that seeks renewal of approval as an approved laboratory, in accordance with this rule.

~~Q.~~ **“License”** means the document issued by the department granting the legal right to produce and distribute medical cannabis for a specified period of time.

**QR.** “Licensed producer” means a person or entity licensed to produce medical cannabis.

**RS.** “Licensure” means the process by which the department grants permission to an applicant to produce ~~or possess~~ cannabis.

**S** **T.** “Lot” means an identified portion of a batch, that is uniform and that is intended to meet specifications for identity, strength, and composition; or, in the case of a cannabis-derived product or concentrate, an identified quantity produced in a specified period of time in a manner that is uniform and that is intended to meet specifications for identity, strength, and composition.

**U.** “Male plant” means a male cannabis plant.

**V.** “Manufacture” means to make or otherwise produce cannabis-derived product or concentrate.

**W.** “Manufacturer” means a business entity that manufactures cannabis-derived product, that has been approved for this purpose by the medical cannabis program.

**X.** “Mature female plant” means a harvestable female cannabis plant that is flowering.

**FY.** “Medical cannabis program” means the administrative body of the ~~New Mexico public health division~~ department charged with the management of the medical cannabis program and enforcement of program regulations, to include issuance of registry identification cards, licensing of producers, and regulation of manufacturing and distribution systems, administration of public hearings and administration of informal administrative reviews.

**UZ.** “Medical cannabis program manager” means the administrator of the ~~New Mexico department of health, public health division~~ medical cannabis program who holds that title.

**VAA.** “Medical director” means a medical practitioner designated by the department to determine whether the medical condition of an applicant qualifies as a debilitating medical condition eligible for enrollment in the program, and to perform other duties.

**WBB.** “Medical provider certification for patient eligibility form” means a written certification form provided by the medical cannabis program signed by a patient's practitioner that, in the practitioner's professional opinion, the patient has a debilitating medical condition as defined by the act or this part and would be anticipated to benefit from the use of cannabis.

**XCC.** “Minor” means an individual less than eighteen (18) years of age.

**YDD.** “Paraphernalia” means any equipment, product, or material of any kind that is primarily intended or designed for use in compounding, converting, processing, preparing, inhaling, or otherwise introducing cannabis or its derivatives into the human body.

**Z.** “Participant ~~EE.~~ “Patient enrollment/re-enrollment form” means the registry identification card application form for ~~adult-qualified~~ patient applicants provided by the medical cannabis program.

**AAFF.** “Personal production license” means a license issued to a qualified patient, ~~eighteen (18) years of age or older,~~ participating in the medical cannabis program, ~~or to a qualified patient's primary caregiver,~~ to permit the qualified patient ~~or primary caregiver~~ to produce medical cannabis for the qualified patient's personal use, consistent with the requirements of this rule.

**BBGG.** “Petitioner” means any New Mexico resident or association of New Mexico residents petitioning the advisory board for the inclusion of a new medical condition, medical treatment or disease to be added to the list of debilitating medical conditions that qualify for the use of cannabis.

**CEHH.** “Plant” means any cannabis plant, cutting, ~~trimming~~ or clone that has roots or that is cultivated with the intention of growing roots.

**DDII.** “Policy” means a written statement of principles that guides and determines present and future decisions and actions of the licensed producer.

**EEJJ.** “Practitioner” means a person licensed in New Mexico to prescribe and administer drugs that are subject to the Controlled Substances Act, Sections 30-31-1 *et seq.*, NMSA (1978).

**FFKK.** “Primary caregiver” means a resident of New Mexico who is at least eighteen (18) years of age and who has been designated by the qualified patient or ~~patient's~~ their representative and the patient's practitioner as being necessary to take responsibility for managing the well-being of a qualified patient with respect to the medical use of cannabis pursuant to the provisions of the Lynn and Erin Compassionate Use Act, NMSA 1978, Section 26-2B-1 *et seq.*

**GLLL.** “Primary caregiver application form” means the registry identification card application form provided by the medical cannabis program.

**HHMM.** “Private entity” means a private, non-profit organization that applies to become or is licensed as a producer and distributor of cannabis, ~~concentrates or cannabis-derived products.~~

~~\_\_\_\_\_~~ ~~HH~~ ~~NN~~. **“Proficiency testing”** means testing conducted by the department or its agent to determine the ability of a laboratory applicant or approved laboratory to accurately identify presence, quantity or other factors pertaining to a given analyte.

~~\_\_\_\_\_~~ ~~OO~~. **“Qualified patient”** means a resident of New Mexico who has been diagnosed by a practitioner as having a debilitating medical condition and has received a registry identification card issued pursuant to the requirements of the act or department rules.

~~\_\_\_\_\_~~ ~~JJPP~~. **“Registry identification card”** means a document issued and owned by the department which identifies a qualified patient authorized to engage in the use of cannabis for a debilitating medical condition or a document issued by the department which identifies a primary caregiver authorized to engage in the intrastate possession and administration of cannabis for the sole use of the qualified patient.

~~\_\_\_\_\_~~ ~~KKQQ~~. **“Representative”** means an individual designated as the applicant’s or petitioner’s agent, guardian, surrogate, or other legally appointed or authorized health care decision maker ~~pursuant to the Uniform Health Care Decisions Act, Sections 24-7A-1 et seq. (NMSA 2007).~~

~~\_\_\_\_\_~~ ~~LLRR~~. **“Secretary”** means the secretary of the New Mexico department of health.

~~\_\_\_\_\_~~ ~~MMSS~~. **“Secure grounds”** means a facility that provides a safe environment to avoid loss or theft.

~~\_\_\_\_\_~~ ~~NNTT~~. **“Security alarm system”** means any device or series of devices capable of alerting law enforcement, including, but not limited to, a signal system interconnected with a radio frequency method such as cellular, private radio signals, or other mechanical or electronic device used to detect ~~an~~ or report an emergency or unauthorized intrusion.

~~\_\_\_\_\_~~ ~~OOUU~~. **“Security policy”** means the instruction manual or pamphlet adopted or developed by the licensed producer containing security policies, safety and security procedures, personal safety and crime prevention techniques.

~~\_\_\_\_\_~~ ~~PPVV~~. **“Seedling”** means a cannabis plant that has no flowers.

~~\_\_\_\_\_~~ ~~QQ~~. **“Submission date”** means ~~the date of submission of the last item in an application, petition or proposal.~~

~~\_\_\_\_\_~~ ~~RRWW~~. **“Segregate”** means to separate and withhold from use or sale batches, lots, cannabis, usable cannabis or cannabis-derived products in order to first determine its suitability for use through testing by an approved laboratory.

~~\_\_\_\_\_~~ ~~XX~~. **“THC”** means tetrahydrocannabinol, the primary psychoactive ingredient in cannabis.

~~\_\_\_\_\_~~ ~~YY~~. **“Technical evidence”** means scientific, clinical, medical or other specialized testimony, or evidence, but does not include legal argument, general comments, or statements of policy or position concerning matters at issue in the hearing.

~~\_\_\_\_\_~~ ~~SS~~. **“Topical treatment”** means a transectaneous therapeutic cannabis extract formulation.

~~\_\_\_\_\_~~ ~~TT~~ ~~ZZ~~. **“Testing”** means the process and procedures provided by an approved laboratory for testing of cannabis and cannabis derived products, consistent with provisions of this rule.

~~\_\_\_\_\_~~ ~~AAA~~. **“Unit”** means a quantity of usable cannabis, concentrate or cannabis-derived product that is used in identifying the maximum supply that a qualified patient may possess for purposes of department rules.

~~\_\_\_\_\_~~ ~~BBB~~. **“Usable cannabis”** means the dried leaves and flowers of the female ~~cannabis~~ cannabis plant and any mixture or preparation thereof cannabis-derived products, including ~~ointments~~ concentrates, but does not include the ~~seedlings, seeds, stalks, or roots of the plant.~~

[7.34.4.7 NMAC - Rp, 7.34.4.7 NMAC, ~~12/30/2010~~ 7/15/2014]

#### 7.34.4.8 PRODUCER LICENSING; GENERAL PROVISIONS:

##### A. The department may license two classes of producers:

(1) A qualified patient who ~~shall produce~~ holds a valid personal production license. A qualified patient who holds a valid personal production license is authorized to possess no more than two (2) mature female plants and a combined total of six (6) seedlings and male plants, and may possess no more than an adequate supply of usable cannabis for the qualified patient’s, as specified in department rule. A personal use only; and who production license holder may additionally obtain ~~useable~~ usable cannabis, seeds or plants from licensed non-profit producers.

(2) A non-profit private entity that operates a facility and, at any one time, is limited to a total of no greater than one-hundred-and-fifty (150) mature female plants and a collective total of no greater than three hundred (300) seedlings and male plants, and an inventory of usable cannabis and seeds that reflects current patient needs, and that shall sell cannabis with a consistent unit price, without volume discounts or promotional sales based on the

quantity purchased. A non-profit private entity shall not possess a quantity of either mature female plants or seedlings and male plants that exceeds the quantities authorized by their licensure and associated licensing fee. A licensed non-profit producer may obtain plants, seeds and ~~usable~~ cannabis from other licensed non-profit producers.

**B. Limitation on distribution:** A private non-profit entity shall not knowingly sell or otherwise distribute usable cannabis to any person or entity that is not authorized to possess and receive the usable cannabis pursuant to department rules.

**C. Processing of production applications:**

(1) The issuance of an application ~~form~~ is in no way a guarantee that the completed application will be accepted or that a license will be granted. Information provided by the applicant and used by the licensing authority for the licensing process shall be accurate and truthful. Any applicant that fails to participate in good faith or that falsifies information presented in the licensing process shall have its application denied by the department.

(2) The number of licenses issued by the department to non-profit private entities, and the determination of which non-profit entities shall be licensed, shall be determined at the discretion of the secretary, which determination shall constitute the final administrative decision of the department.

(3) A non-profit private entity whose application for licensure is not approved ~~by the secretary~~ shall not be entitled to further administrative review.

**ED. Factors considered:** The secretary shall consider the overall health needs of qualified patients and the safety of the public in determining the number of licenses to be issued to non-profit private entities and shall further consider:

(1) the sufficiency of the overall supply available to qualified patients statewide;

(2) the service location of the applicant;

(3) the applicant's production plan, including but not limited to ensure purity, consistency of dose, the applicant's plan for the growth, cultivation and the various forms of applications to be provided; i.e., topical, oral, tinctures, etc.; harvesting of medical cannabis.

(4) the applicant's sales and distribution plan, including but not limited to the applicant's plan for sale of medical cannabis, plan for delivery (if any) to qualified patients, and the forms of usable cannabis and cannabis-derived products to be sold or distributed;

(5) the applicant's skill and knowledge of organic growing methods horticulture and cannabis production technology, as well as the applicant's knowledge of current Good Manufacturing Practices and NMDA pesticide registration and Worker Protection Standards to ensure a safe product and environment;

~~(5) — the quality of~~ (6) the security plan proposed, including location, security devices employed and staffing;

(7) the applicant's quality assurance plans in place plan, including provision but not limited to the applicant's plan to ensure purity, consistency of dose, as well as the applicant's plan for periodic routine testing by a department approved laboratory;

(8) the experience and expertise of the non-profit board members; and

(9) the financial resources available to the applicant for licensure and operations;

(10) the facilities available to the applicant for production, distribution, storage, and other purposes, and the applicant's ownership of the property, buildings or other facilities identified in the production and distribution plan, as applicable; and

(11) other relevant factors.

**EE. Production and distribution of medical cannabis by a licensed non-profit private entity—; use of couriers:** Production and distribution of medical cannabis by a licensed non-profit private entity producer to a qualified patient or primary caregiver shall take place at locations described in the non-profit entity's production and distribution plan approved by the department, and shall not take place at locations that are within three hundred (300) feet of any school, church or daycare center. A licensed non-profit producer may, consistent with this rule, and with the consent of a purchasing qualified patient or primary caregiver, utilize an approved courier to transport usable cannabis to a qualified patient or primary caregiver, and may for this purpose share with an approved courier the contact information of the purchasing qualified patient or primary caregiver. A licensed non-profit producer shall not identify any person as an intended recipient of usable cannabis who is not either a qualified patient or primary caregiver.

**EF. Verification of application information:** The department may verify information contained in each application and accompanying documentation by:

(1) contacting the applicant by telephone, mail, or electronic mail;

(2) conducting an on-site visit;

(3) requiring a face-to-face meeting and the production of additional identification materials if proof of identity is uncertain; and

(4) requiring additional relevant information as the department deems necessary.

**FG. Cooperation with the department:** Upon submitting an application, an applicant shall fully cooperate with the department and shall timely respond to requests for information or documentation. Failure to cooperate with a request of the department may result in the application being denied or otherwise declared incomplete.

**G. ~~Non-profit private entity~~ H. Criminal history screening requirements:** All ~~applicants for personal production licensure, and all persons associated with a licensed non-profit private entity production facility producer or non-profit producer-applicant, manufacturer or manufacturer-applicant, approved laboratory or laboratory applicant, and approved courier or courier-applicant,~~ shall consent to and undergo a nationwide and statewide criminal history screening background check. This includes ~~qualified patients,~~ board members, persons having direct or indirect authority over management or policies, ~~and employees, contractors and agents.~~ ~~Background check documentation shall be submitted annually for approval to the department with the applicant's renewal materials and prior to an individual assumes any duties or responsibilities for a non-profit entity, manufacturer, laboratory or courier. Background check documentation shall be received by the medical cannabis program, and the individual shall be approved by the program, before the individual begins to provide any work or services to the producer, manufacturer, laboratory or courier.~~

(1) **Criminal history screening fees:** All applicable fees associated with the nationwide and statewide criminal history screening background checks shall be paid by the individual ~~or the,~~ non-profit private entity, ~~manufacturer, laboratory or courier.~~

(2) **Disqualifying convictions:** Individuals convicted of a felony violation of Section 30-31-20; ~~(trafficking of a controlled substance), 30-31-21; (distributing a controlled substance to a minor), or 30-31-22 NMSA 1978; (distributing a controlled substance),~~ or a violation of any equivalent federal statute or equivalent statute from any other jurisdiction, shall be prohibited from ~~either holding a personal production license or participating or being associated with a production facility either a non-profit producer licensed under this rule, an approved laboratory, an approved manufacturer, or an approved courier.~~ If an individual has been convicted of a felony violation of ~~Section 30-31-1 et seq., NMSA 1978~~ the NM Controlled Substances Act other than Sections 30-31-20 through 30-31-22, or has been convicted of any equivalent federal statute or equivalent statute from any other jurisdiction, and the final completion of the entirety of the associated sentence of such conviction has been less than five (5) years from the date of the individual's anticipated association with the production facility, then the individual shall be prohibited from ~~holding personal production licensure, serving on the board of a licensed non-profit producer, or working for the licensed producer or approved entity.~~ An individual who is disqualified shall be notified of his or her disqualification. If ~~the~~an individual has been convicted of more than one (1) felony violation of ~~Section 30-31-1 et seq., NMSA 1978~~ the above-cited sections of the NM Controlled Substances Act or an equivalent federal statute or equivalent statute from any other jurisdiction, the individual shall be notified that he or she is permanently prohibited from ~~holding personal production licensure, or participating or being associated with a production facility licensed under this rule~~ non-profit producer, approved manufacturer, approved laboratory, or approved courier. Any violation of this subsection shall result in the immediate revocation of any privilege granted under this rule and the act.

**H. Board membership requirements for private entities:** The board of directors for a private non-profit applicant or licensee shall include at a minimum five (5) voting members, including one (1) medical provider limited to a physician (MD or DO), a registered nurse, nurse practitioner, licensed practical nurse or physician assistant, and three (3) patients currently qualified under the Lynn and Erin Compassionate Use Act.

(1) For purposes of board membership, a single individual may not qualify as both the patient and as the medical provider.

(2) Members of the board of directors for a non-profit private entity shall be residents of New Mexico.

(3) ~~Beginning July 1, 2011 and continuing thereafter,~~ No member of ~~the~~a non-profit producer's board of directors may ~~at any given time~~ serve on more than one single board of directors for licensed non-profit producers, ~~or be employed by another non-profit producer.~~

~~I. J. Investment or other financial interest in a licensed non-profit producer:~~ No person or entity who has loaned money or property to, invested in, or who otherwise holds a financial interest in the operation or property of a non-profit producer licensed pursuant to this rule, may invest in or otherwise hold a financial interest in another non-profit producer licensed pursuant to this rule. ~~A non-profit producer licensed~~

pursuant to this rule shall not accept money or property from any person who holds any such financial interest in another licensed non-profit producer.

**K. Prohibition against shared management and employees:**

(1) A non-profit producer licensed pursuant to this rule, and a non-profit producer-applicant, shall not be managed, directed, or controlled in any manner by a person who manages, directs, or exercises control of another non-profit producer licensed pursuant to this rule.

(2) A non-profit producer licensed pursuant to this rule shall not employ any person employed by another non-profit producer licensed pursuant to this rule.

**L. Limitation on number of production facilities:** A licensed non-profit producer shall conduct its production operations at a single physical location approved by the department. An additional production facility or facilities may be allowed at the department's discretion if the non-profit entity is approved to grow more than fifty (50) mature female plants.

**M. Limitation on sales within ninety (90) consecutive calendar days:** A licensed non-profit producer shall not sell or distribute usable cannabis to a qualified patient or primary caregiver in a total quantity that exceeds one-hundred-and-seventy (170) units, as described in department rules concerning patient registry identification cards, within any 90-day period.

**N. Maximum concentration of THC in concentrates:** A licensed non-profit producer shall not sell or otherwise distribute a concentrated cannabis derived product to a qualified patient or primary caregiver that contains greater than sixty (60) percent THC by weight, unless the qualified patient or primary caregiver presents proof of a medical exception granted by the department.

**O. Private entity policies and procedures:** The private non-profit entity shall develop, implement and maintain on the premises policies and procedures relating to the medical cannabis program, which shall at a minimum include the following:

(1) distribution criteria for qualified patients or primary caregivers appropriate for cannabis services, to include clear ~~identifiable, legible~~ photocopies of the registry ~~identification card and New Mexico photo~~ identification card of every qualified patient or primary caregiver served by the private entity;

(2) ~~testing criteria and procedures, which shall be consistent with the testing requirements of this rule;~~

(3) alcohol and drug-free work place policies and procedures;

~~(34) an attestation that no firearms will be permitted on any premises used for production or distribution by the non-profit entity;~~

(5) employee policies and procedures to address the following requirements:

(a) job descriptions or employment contracts developed for every employee that identify duties, authority, responsibilities, qualifications and supervision; ~~and~~

(b) training materials concerning adherence to state ~~and federal~~ confidentiality laws;

~~(4) (c) an attestation that no employee will at any given time be simultaneously employed by another non-profit producer; and~~

~~(d) an attestation that no person will volunteer to either produce, manufacture or distribute cannabis, cannabis-derived products or concentrates for the non-profit producer;~~

(6) personnel records for each employee that include an application for employment and a record of any disciplinary action taken;

(57) on-site training curricula, or contracts with outside resources capable of meeting employee training needs, to include, at a minimum, the following topics:

(a) professional conduct, ethics and patient confidentiality; and

(b) informational developments in the field of medical use of cannabis;

(68) employee safety and security training materials provided to each employee at the time of his or her initial appointment, to include:

(a) training in the proper use of security measures and controls that have been adopted; and

(b) specific procedural instructions regarding how to respond to an emergency, including robbery or a violent accident;

(79) a general written security policy, to address at a minimum:

(a) safety and security procedures;

(b) personal safety; and

(c) crime prevention techniques;

(810) training documentation prepared for each employee and statements signed by employees indicating the topics discussed (to include names and titles of presenters) and the date, time and place the employee received said training; ~~and~~

- (911) a written policy regarding the right of the private entity to refuse service; and  
~~J~~ (12) such other policies or procedures as the department may require.
- P. Retention of training documentation:** A private non-profit entity shall maintain documentation of an employee's training for a period of at least six (6) months after termination of an employee's employment. Employee training documentation shall be made available within twenty-four (24) hours of a department representative's request; the twenty-four (24) hour period shall exclude holidays and weekends.
- KQ. Licensure periods:**
- (1) **Licensure period for private entities:** The licensure period of a ~~private entity licensed non-profit producer~~ shall be from ~~January~~ July 1st (or the date of approval of the licensure application, if later) through ~~December 31st~~ June 30th of a given year. A license that was issued prior to the promulgation of this provision that is scheduled to expire ~~before December 31, 2014~~ prior to June 30, 2014 shall be extended to that date.
- (2) **Licensure period for qualified patient producers:** A qualified patient's personal production license shall expire annually at the end of their enrollment in the NM medical cannabis program.
- ~~L~~ (3) **Return of a license or identification card:** Licenses and identification cards issued by the department are the property of the department and shall be returned to the department upon a producer's withdrawal from the program, upon termination of a card holder's employment with a licensed non-profit producer, upon suspension or revocation, or upon demand of the department.
- R. Amended license:** A licensed producer shall submit to the department an application form for an amended license, and shall obtain approval from the department, at least thirty (30) business days prior to implementing any:
- (1) change of location of a qualified patient who also holds a personal production license;
- (2) change of location of ~~the~~ private non-profit ~~entity~~ entity's production or distribution facilities, change of directors, change of ownership of production or distribution facilities, private entity name, capacity or any physical modification or addition to the facility; and
- (3) substantial change to a private entity's production ~~and~~ plan or distribution plan, including any change to the type(s) of products produced, the private entity's method(s) of distribution, and security plan.
- MS. Application for renewal of an annual production license:**
- (1) **Deadline for private entities.** Each licensed ~~non-profit~~ producer shall apply for renewal of its annual license no later than ~~December~~ June 1st of each year by submitting a renewal application to the department. The department shall provide the renewal application requirements no later than ~~October~~ April 1st of each year.
- (2) **Deadline for qualified patients.** ~~Each patient licensed for a personal production license holders:~~ A patient who holds personal production licensure shall apply for renewal of their annual license no later than thirty (30) days prior to the expiration of the license by submitting a renewal application to the department.
- (3) **General submission requirements for qualified patients:** Qualified patients applying for personal production licensure shall submit:
- (a) an application for ~~issuance or~~ renewal of a personal production license; and
- (b) a non-refundable thirty-dollar (\$30) application fee, except the fee may be waived upon a showing that the income of the qualified patient is equal to or lesser than two hundred percent (200%) of the federal poverty guidelines established by Medicaid enrollment with the U.S. department of health and human services;
- (c) a fifty dollar (\$50) payment is required for replacement of a license. A lost or stolen identification card shall be reported as soon as practicable to the medical cannabis program.
- (4) **General submission requirements for private entities:** Private entities shall submit:
- (a) an application for renewal of license; and
- (b) applicable non-refundable licensure renewal fees.
- NT. Non-transferable registration of license:**
- (1) A license shall not be transferred by assignment or otherwise to other persons or locations. Unless the licensed producer applies for and receives an amended license, the license shall be void and returned to the ~~licensing authority~~ department when any one of the following situations occurs:
- (a) ownership of the facility changes;
- (b) location change;
- (c) change in licensed producer;
- (d) the discontinuance of operation; or
- (e) the removal of all medical cannabis from the facility by lawful state authority.
- (2) Transactions, which do not constitute a change of ownership, include the following:
- (a) when applicable, changes in the membership of a corporate board of directors or board of trustees; and

(b) two (2) or more corporations merge and the originally licensed corporation survives.

~~(3) Management agreements are generally not considered a change in ownership if the licensed producer continues to retain ultimate authority for the operation of the facility. However, if the ultimate authority is surrendered and transferred from the licensed producer to a new manager, then a change of ownership has occurred.~~

~~Q~~ **U. Automatic expiration of license:**

(1) A license shall expire at 11:59 p.m. on the day indicated on the license as the expiration date, unless the license was renewed at an earlier date, suspended or revoked.

(2) A private entity that intends to voluntarily close or is involuntarily closed shall notify the licensing authority no later than thirty (30) calendar days prior to closure. All private non-profit entities shall notify all qualified patients or the primary caregivers prior to expiration of the license. Any unused medical cannabis ~~must~~ shall be turned over to local law enforcement, destroyed by the producer, or donated to patients or provided to another non-profit producer to be donated to patients. A producer that destroys medical cannabis shall submit documentation of that destruction to the department.

**PV. Display of license:** The licensed producer shall maintain the license safely at the production location and be able to produce the license immediately upon request by the department or law enforcement.

~~Q~~

**W. Fees applicable to applicants and licensees:**

(1) **Private non-profit application fee:** A non-profit producer shall submit with its initial application ~~a non-refundable~~ application fee of ~~one~~ ten thousand dollars (\$~~10,000~~), If the application is denied, the department shall issue a refund of nine thousand dollars (\$9,000) to the applicant.

(2) **Private non-profit renewal license fee:** A non-profit private entity that ~~has been~~ is licensed ~~for more than six months~~ shall ~~additionally~~ submit to the medical cannabis program a non-refundable renewal licensure fee before beginning operations and no later than ~~December~~ June 1st of each renewal year of:

(a) ~~five~~ twenty thousand dollars (\$~~50,000~~) ~~if for every fifty (50) mature female plants to be possessed by the producer has been licensed for less than, up to a maximum of one year but more than six months;~~ hundred-and-fifty total mature female plants; and

(b) ~~ten~~ thousand dollars (\$~~10,000~~) ~~if for every one-hundred (100) seedlings and male plants, collectively, to be possessed by the producer has been licensed for more than one year;~~

~~(c) twenty thousand dollars (\$20,000) if the producer has been licensed for more than two years;~~

~~(d) thirty thousand dollars (\$30,000) if the producer has been licensed for more than, up to a maximum of three years;~~ hundred (300) seedlings and male plants, collectively.

(3) **Qualified patient ~~producer~~ personal production fees:** A qualified patient shall submit with each initial application and renewal application for personal production licensure a fee of thirty dollars (\$30), unless the fee is waived on a showing ~~that the income of the qualified patient is equal to or lesser than two hundred percent (200%) of the federal poverty guidelines of Medicaid eligibility~~ established by the U.S. department of health and human services.

(4) **Replacement license fee:** A fifty dollar (\$50) payment is required for replacement of a license.

(5) **Payment:** Fees shall be paid by check, money order, or any other form of payment approved by the medical cannabis program manager or designee, and shall be made payable to the ~~harm reduction~~ medical cannabis program of the department.

**X. Inventory and sales equipment:** The department may require a licensed non-profit producer to utilize specified equipment, software and services for purposes of tracking inventory, sales, and other information, and for the purpose of reporting that information to the department of health.

[7.34.4.8 NMAC - Rp. 7.34.4.8 NMAC, 7/15/2014]

**7.34.4.9 NON-PROFIT PRODUCER TESTING OF USABLE CANNABIS:**

**A. Non-profit producer testing:** All usable cannabis produced by a non-profit producer shall be sampled for testing purposes by the licensed non-profit producer, and those samples shall be tested for the presence of microbiological contaminants, mycotoxins, pesticide chemical residue, and heavy metals, and for quantity of THC, consistent with the requirements of this rule. Each batch of usable cannabis shall be segregated and sampled, and each sample shall be tested by an approved laboratory, and determined by the licensed non-profit producer to

have passed the following individual testing requirements, before usable cannabis from that batch is made available for sale or distribution.

**B. Testing of concentrates for quantity of THC:** A non-profit producer shall test a concentrated cannabis derived product for the quantity of THC contained in the concentrate prior to its sale, distribution or other use.

**C. Individual testing requirements:**

**(1) Microbiological test:** For purposes of the microbiological test, a cannabis sample may be deemed to have passed if it satisfies the standards set forth in Section 1111 of the United States Pharmacopeia, which can be obtained at <http://www.usp.org>.

**(2) Mycotoxin test:** For purposes of the mycotoxin test, a cannabis sample may be deemed to have passed if it meets the following standards:

| <u>Test</u>  | <u>Specification</u>   |
|--------------|------------------------|
| Alfatoxin B1 | <20 uG/KG of substance |
| Alfatoxin B2 | <20 uG/KG of substance |
| Alfatoxin O1 | <20 uG/KG of substance |
| Alfatoxin O2 | <20 uG/KG of substance |
| Ochratoxin A | <20 uG/KG of substance |

**(3) Heavy metal test:** For purposes of the heavy metal test, a cannabis sample may be deemed to have passed if it meets the following standards:

| <u>Metal</u> | <u>Acceptable limits uG/KG</u> |
|--------------|--------------------------------|
| Arsenic      | <0.14                          |
| Cadmium      | <0.09                          |
| Lead         | <0.29                          |
| Mercury      | <0.29                          |

**R. (4) Pesticide chemical residue:** For purposes of the pesticide chemical residue test, a cannabis sample may be deemed to have passed if it satisfies the most stringent acceptable standard for a pesticide chemical residue in any food item as set forth in Subpart C of the federal Environmental Protection Agency's regulations for Tolerances and Exemptions for Pesticide Chemical Residues in Food, 40 CFR 180.

**(5) Additional testing:** The department may require additional testing of cannabis and cannabis derived products by non-profit producers, as it deems appropriate.

**(6) Release of batch after testing:** A licensed non-profit producer may, consistent with the

provisions of this rule, release the entire batch of usable cannabis for immediate manufacturing or sale, provided that the sample taken from the batch passes the microbiological, mycotoxin, heavy metal and pesticide chemical residue tests.

**D. Procedures for testing:** A licensed non-profit producer shall ensure that the following testing procedures are followed:

**(1) Sampling and segregation:** a licensed non-profit producer shall remove a sample of no less than three (3) grams from every batch of harvested cannabis, and no less than 0.5 grams from every batch of concentrated cannabis-derived product, and transfer the sample to an approved laboratory for testing. The remainder of the batch of usable cannabis or concentrated cannabis-derived product shall be segregated until the licensed non-profit producer receives the results of laboratory testing report and determines whether the batch is safe for human consumption.

**(2) Documentation:** A licensed non-profit producer shall appropriately document the sampling and testing of all usable cannabis and concentrated cannabis-derived product, and shall utilize a department approved laboratory for the purpose of testing usable cannabis.

**(3) Remediation:** If a sample does not pass testing, the producer shall determine whether remediation is appropriate and test another sample from the batch at issue, or identify manufacturing options that will render the cannabis-derived product safe and retest in accordance with the requirements of this section:

**(4) Notice and destruction:** If the batch cannot be remediated to where it meets the testing requirements of this rule, the non-profit producer shall notify the medical cannabis program within twenty-four (24) hours, and confirm the destruction and disposal of the cannabis or concentrated cannabis-derived product:

**(5) Testing and remediation protocols:** A licensed non-profit producer shall adopt and maintain on the premises protocols regarding sampling, sample testing, remediation, and retesting, consistent with this rule.

**(6) Preservation and inspection of testing records:** A licensed non-profit producer shall maintain all results of laboratory tests conducted on cannabis or cannabis derived products produced by the licensed non-profit producer or its contractor, and shall make those results available to qualified patients and primary caregivers enrolled in the medical cannabis program upon request.

**(7) Disciplinary action:** Repeated failure to pass testing may result in the imposition of disciplinary action(s) by the department, consistent with this rule.

[7.34.4.9 NMAC - N. 7/15/2014]

**7.34.4.10 COMPLAINT PROCEDURE; DEPARTMENT TESTING:** If the department or its designee receives a complaint regarding the presence of mold, bacteria or another contaminant in cannabis produced by a licensed non-profit or patient who holds a personal production license, or if the department or its designee has reason to believe that the presence of mold, bacteria or another contaminant may jeopardize the health of a patient, the department or its designee may conduct an unannounced visit to the producer and may require the producer to provide samples of medical cannabis for testing, by the department. Producers shall bear the cost of any testing required by the department. Medical cannabis program employees or their designees may possess those medical cannabis samples for the sole purposes of testing or transport to a testing facility. The department or its designee shall comply with the following testing requirements:

~~(1) (A)~~ the department or its designee shall maintain chain of custody documentation for any medical cannabis samples taken;

~~(2) (B)~~ a written receipt shall be given to the producer for all testing samples;

~~(3) (C)~~ all testing samples shall be placed into a sealed container and clearly labeled;

~~(4) (D)~~ all testing samples shall be tested by ~~DOH~~the department or a designated testing facility;

~~(5) (E)~~ no more than eight (8) grams of medical cannabis shall be gathered for testing purposes from a non-profit medical cannabis producer on any single occasion; and

~~(6) (F)~~ no more than one (1) gram of medical cannabis shall be gathered for testing purposes from a patient who holds a personal production license on any single occasion.

[7.34.4.8 NMAC - Rp, 7.34.4.8~~10~~ NMAC, ~~12/30/2010~~7/15/2014]

**7.34.4.11 USE OF PESTICIDES BY LICENSED PRODUCERS:** All pesticides utilized by a licensed producer in the growth or manufacture of cannabis shall be registered by the New Mexico Department of Agriculture before being used by the licensed producer. [40 CFR 180.1 et seq.]. Pesticides shall not be used in a quantity or concentration greater than that recommended by the manufacturer.

[7.34.4.11 NMAC - N. 7/15/2014]

**7.34.4.12 DEPARTMENT APPROVAL OF MANUFACTURERS OF CANNABIS DERIVED PRODUCTS; GENERAL PROVISIONS:**

**A. Submittal of applications:** A manufacturer applicant shall submit an authorized application form to the program with each initial application and renewal application, together with a fee of one thousand dollars (\$1,000) issued to the medical cannabis program. A manufacturer applicant shall comply with the application requirements of this rule, and shall submit such other information as the manufacturer applicant wishes to provide or such information as the department may request for initial approval or periodic evaluation(s) during the approval period.

**B. Application requirements:** A manufacturer applicant shall submit to the department:

(1) proof that the manufacturer applicant is in good standing with the New Mexico taxation and revenue department;

(2) copies of the manufacturer applicant's articles of incorporation and bylaws, as applicable;

(3) a complete written description of the means that the manufacturer applicant shall employ to safely manufacture cannabis-derived products, including but not limited to hygiene standards consistent with the requirements of this rule;

(4) a list of all persons or business entities having direct or indirect authority over the management or policies of the manufacturer applicant;

(5) a list of all persons or business entities having any ownership interest in any property utilized by the manufacturer applicant, whether direct or indirect, and whether the interest is in land, building(s), or other material, including owners of any business entity that owns all or part of land or building(s) utilized;

(6) a description of the facilities that shall be used in the manufacture of cannabis derived products;

(7) a description of how the manufacturer applicant will obtain cannabis or cannabis concentrates from a licensed non-profit producer, and how the manufacturer applicant will transport cannabis derived products to a licensed non-profit producer, including but not limited to chain of custody documentation;

(8) testing criteria and procedures, which shall be consistent with the testing requirements of this rule;

(9) a general written security policy, to address at a minimum:

(a) safety and security procedures;

(b) personal safety; and

(c) crime prevention techniques;

(10) an attestation that no firearms will be permitted on any premises used for manufacture of cannabis derived products by the manufacturer applicant;

(11) a description of the methods and device or series of devices that shall be used to provide security;

(12) training documentation prepared for each employee of the manufacturer applicant, statements signed by employees indicating the topics discussed (to include names and titles of presenters) and the date, time and place the employee received said training;

(13) employee policies and procedures to address the following requirements:

(a) job descriptions or employment contracts developed for every employee of the manufacturer applicant that identify duties, authority, responsibilities, qualifications and supervision;

(b) training materials concerning adherence to state and federal confidentiality laws;

(c) an attestation that no person will volunteer to manufacture cannabis-derived products or concentrates for the manufacturer;

(14) personnel records for each employee of the manufacturer applicant that include an application for employment and a record of any disciplinary action taken;

(15) employee safety and security training materials provided to each employee of the manufacturer applicant at the time of his or her initial appointment, to include:

(a) training in the proper use of security measures and controls that have been adopted; and

(b) specific procedural instructions regarding how to respond to an emergency, including robbery or a violent accident; and

(16) such other materials as the department may require.

**C. Packaging and labeling:** a manufacturer applicant shall submit a description and sample of the opaque, child resistant packaging of the concentrate or cannabis-derived product that the manufacturer shall utilize, including a label that shall contain:

(1) the name of the entity that produced the cannabis and the name of the manufacturer;

(2) a batch number or code;

(3) a production date or expiration date, including a “use by” or “freeze by” date for products capable of supporting the growth of infectious, toxigenic, or spoilage microorganisms;

(4) the number of units of usable cannabis contained within the product;

(5) instructions for use, including any department approved conditions for which the product is recommended;

(6) warnings for use, including any department approved conditions for which the product is not recommended;

(7) instructions for appropriate storage;

(8) approved laboratory analysis, including the results of strength and composition within ten (10) percent of numbers shown on the package;

(9) the name of the strain, product facts or a nutrition fact panel, and a statement that the product is for medical use by qualified patients, to be kept away from children, and not for resale; and

(10) the name of the department approved testing facility used for active ingredient analysis, microbiological contaminants analysis and chemical/pesticide residue analysis.

**D. Term of approval:** Department approval of a manufacturer shall be for a term of one year, and shall expire after that year, or upon closure of the manufacturer. An approved manufacturer shall apply for renewal of approval annually no later than thirty (30) days prior to expiration.

**E. Identification cards:** Identification cards issued by the department are the property of the department and shall be returned to the department upon termination of the holder’s employment with the approved laboratory, suspension or revocation of approval by the department, or upon demand of the department.  
[7.34.4.12 NMAC - N, 7/15/2014]

**7.34.4.13 STANDARDS FOR MANUFACTURE OF CANNABIS-DERIVED PRODUCTS:** The following are minimum requirements for the manufacture of cannabis-derived products which shall apply to all manufacturers:

**(1) General requirements:** A licensed non-profit producer and a manufacturer shall take reasonable measures and precautions to ensure the following:

**(a)** that all manufacturing shall be done in premises that are in compliance with local ordinances, including but not limited to zoning, occupancy, licensing and building codes;

**(b)** that the manufacturing operation and all equipment, implements and fixtures shall be used exclusively for the production of cannabis derived products and that food processing for personal, staff or the general public shall be prohibited;

**(c)** that all LNPP and manufacturer staff involved in the handling, transportation, manufacture, testing or packaging of cannabis derived products must complete general food handler safety training, such as is commonly available online for a nominal fee;

**(d)** that any person who, by medical examination or supervisory observation, is shown to have, or appears to have, an illness, open lesion, including a boil, sore, or infected wound, or any other abnormal source of microbial contamination for whom there is a reasonable possibility of contact with preparation surfaces for medical cannabis or cannabis derived products, shall be excluded from any operations which may be anticipated to result in such contamination until the condition is corrected;

**(e)** that hand-washing facilities are adequate and convenient, and that they are furnished with running water at a suitable temperature. Hand-washing facilities shall be located in the facility in medical cannabis derived product preparation areas and where good sanitary practices require employees to wash and/or sanitize their hands, and provide effective hand-cleaning and sanitizing preparations and sanitary towel service or suitable drying devices;

**(f)** that all persons involved in preparing or handling medical cannabis or cannabis derived products at the manufacturing operation conform to hygienic practices while on duty, including:

**(i)** maintaining adequate personal cleanliness;

**(ii)** washing hands thoroughly in an adequate hand-washing area before starting work and at any other time when the hands may have become soiled or contaminated;

**(iii)** refraining from preparing or handling medical cannabis or cannabis derived products if the handler has or may have an illness, open lesion, including boils, sores, or infected wounds, or any other abnormal source of microbial contamination, until such condition is corrected;

**(iv)** complying with the other requirements of this section;

**(g)** that there is sufficient space for placement of equipment and storage of materials as is necessary for the maintenance of sanitary operations for production of medical cannabis derived products;

(h) that litter and waste are properly removed, and the operating systems for waste disposal are maintained in an adequate manner so that they do not constitute a source of contamination in areas where medical cannabis or cannabis derived products are exposed;

(i) that floors, walls, and ceilings are constructed in such a manner that they may be adequately cleaned and kept clean and kept in good repair;

(j) that there is adequate safety-type lighting in all areas where medical cannabis or cannabis derived products are processed or stored, and where equipment or utensils are cleaned;

(k) that the manufacturer provides adequate screening or other protection against the entry of pests. Rubbish shall be disposed of so as to minimize the development of odor, minimize the potential for the waste becoming an attractant and harborage or breeding place for pests;

(l) that building, fixtures, and other physical facilities where cannabis derived products are manufactured are maintained in a sanitary condition;

(m) that all contact surfaces, including utensils and equipment used for preparation of cannabis derived products are cleaned and sanitized as frequently as necessary to protect against contamination;

(n) that all equipment and utensils used for preparation of cannabis derived products are designed and of such material and workmanship as to be adequately cleanable, and are properly maintained;

(o) that only EPA registered sanitizing agents are used in manufacturing operations and that they are used in accordance with labeled instructions;

(p) that toxic cleaning compounds, sanitizing agents, and pesticide chemicals shall be identified, held, and stored in a manner that protects against contamination of medical cannabis or cannabis derived products;

(q) that the water supply is sufficient for the operations intended and is derived from a source that is a regulated water system. Private water supplies shall be from a water source that is capable of providing a safe, potable and adequate supply of water to meet the manufacturing facility's needs;

(r) that plumbing shall be of adequate size and design and adequately installed and maintained to carry sufficient quantities of water to required locations throughout the facility; and properly convey sewage and liquid disposable waste from the facility

(s) that there are no cross-connections between the potable and waste water lines;

(t) that the manufacturer provide its employees with adequate, readily accessible toilet facilities that are maintained in a sanitary condition and good repair;

(u) that all operations in the receipt, inspection, transport, segregation, preparation, manufacture, packaging, and storage of medical cannabis or cannabis derived products are conducted in accordance with adequate security and sanitation principles;

(v) that medical cannabis or cannabis derived products that can support the rapid growth of undesirable microorganisms are stored and transported in a manner that prevents the growth of these microorganisms;

(w) that storage and transportation of medical marijuana or cannabis derived products are under conditions that will maintain security and protect medical cannabis or cannabis derived products against physical, chemical, and microbial contamination as well as against deterioration of the medical cannabis or cannabis derived product and the container;

(x) that current material safety data sheets are kept on the premises for all chemicals used, including but not limited to cleaning compounds, sanitizing agents, and pesticides; and

(y) that extraction for the purpose of manufacturing concentrates is conducted in a closed system utilizing an oil extractor solvent such as N-butane or carbon dioxide.

(2) **Prohibited products:** the use of dimethylsulfoxide (DMSO) in the production of cannabis derived products, and the possession of DMSO upon the premises of a manufacturer, is prohibited.

[7.34.4.13 NMAC - N, 7/15/2014]

**7.34.4.14 LABELING OF USABLE CANNABIS:** A non-profit producer shall not sell or otherwise distribute a usable cannabis product that has not been packaged and labeled in accordance with this rule. The label shall identify:

(1) the name of the entity that produced the cannabis, and the name of the manufacturer of the cannabis-derived product (as applicable);

(2) a batch number or code;

(3) a production date or expiration date, including a "use by" or "freeze by" date for products capable of supporting the growth of infectious, toxigenic, or spoilage microorganisms;

(4) the number of units of usable cannabis or concentrated cannabis-derived product contained within the product, as identified in department rules for the enrollment of qualified patients;

(5) if the product is a concentrated cannabis derived product: the quantity of THC contained in the product, by weight;

(6) instructions for use, including any department approved conditions for which the product is recommended;

(7) warnings for use, including any department approved conditions for which the product is not recommended;

(8) instructions for appropriate storage;

(9) approved laboratory analysis, including the results of strength and composition within ten (10) percent of numbers shown on the package;

(10) the name of the strain, product facts or a nutrition fact panel, and a statement that the product is for medical use by qualified patients, to be kept away from children, and not for resale; and

(11) the name of the department approved testing facility used for active ingredient analysis, microbiological contaminants analysis and chemical/pesticide residue analysis, and quantity of THC (as applicable). [7.34.4.14 NMAC - N, 7/15/2014]

**7.34.4.15 DEPARTMENT-APPROVED TESTING LABORATORIES; GENERAL PROVISIONS:** A laboratory applicant shall comply with the application requirements of this rule, and shall submit such other information as the laboratory applicant wishes to provide or such information as the department may request for initial approval and periodic evaluations during the approval period.

**(A) Testing categories:** A laboratory may apply to become approved by the department as an approved laboratory for the testing of cannabis and cannabis derived products in all or any one of the following categories:

(1) mycotoxin analysis;

(2) microbiological contaminant analysis;

(3) heavy metal analysis;

(4) pesticide chemical residue analysis; or

(5) quantity of THC.

**(B) Fee:** A laboratory applicant shall submit to the program with each initial application and renewal application for continued approval a non-refundable application fee of two-thousand-and-two-hundred dollars (\$2,200), payable to the medical cannabis program.

**(C) Application materials:** A laboratory applicant shall submit to the program with each initial application and renewal application for continued approval the following:

(1) standard operating procedures to be followed by the laboratory, including but not limited to policies and procedures to be used in performing analysis of samples;

(2) a description of the type of tests to be conducted by the laboratory applicant, which may include, but are not limited to, testing for microbiological contaminants, mycotoxins, pesticide chemical residue, heavy metals, THC content, identity, purity, strength, composition, or nutritional content and other quality factors;

(3) quality control criteria for the test(s) that the applicant intends to conduct;

(4) evidence that validates the accuracy of the test(s) to be conducted by the laboratory applicant as performed in the applicant's laboratory;

(5) proof that the laboratory applicant is in good standing with the New Mexico taxation and revenue department;

(6) copies of the laboratory applicant articles of incorporation and bylaws, as applicable;

(7) a list of all persons or business entities having direct or indirect authority over the management or policies of the laboratory applicant;

(8) a list of all persons or business entities having any ownership interest in any property utilized by the laboratory applicant, whether direct or indirect, and whether the interest is in land, building(s), or other material, including owners of any business entity that owns all or part of land or building(s) utilized;

(9) a description of the facilities and equipment that shall be used in the operation of the laboratory applicant;

(10) a description of how the laboratory applicant will ensure and document chain of custody of any samples held or tested by the laboratory;

(11) a general written security policy, to address at a minimum safety and security procedures;

(12) an attestation that no firearms will be permitted on any premises used by the laboratory applicant;

(13) a description of the methods and device or series of devices that shall be used to provide security;

(14) training documentation prepared for each employee of the laboratory applicant, statements signed by employees indicating the topics discussed (to include names and titles of presenters) and the date, time and place the employee received said training;

(15) personnel records for each employee of the manufacturer applicant that include an application for employment and a record of any disciplinary action taken;

(16) employee safety and security training materials provided to each employee of the manufacturer applicant at the time of his or her initial appointment, to include training in the proper use of security measures and controls that have been adopted, and specific procedural instructions regarding how to respond to an emergency, including robbery or a violent accident; and

(17) such other materials as the department may require.

**(D) Materials to be maintained on premises:** An approved laboratory shall maintain on its premises, and shall promptly present to the department upon request:

(1) personnel documentation including, but not limited to employment records, job descriptions, education and training requirements of the laboratory, and documentation of education and training provided to staff for the purpose of performance of assigned functions;

(2) requirements concerning laboratory operations, business licensing and security procedures;

(3) standards for receipt, handling and disposition of samples of usable cannabis;

(4) equipment information detailing the type of equipment used, inspection standards and practices, testing and calibration schedules and records, and standards for cleaning and maintenance of equipment;

(5) reagents, solutions and reference standards including, but not limited to standards for labeling, storage, and expiration and requalification dates and records;

(6) reference standards, acquired or internally produced, including the certificate of analysis;

(7) sample analysis procedures including, but not limited to procedures for the use of only primary or secondary standards for quantitative analyses;

(8) documentation demonstrating that the analytical methods used by the laboratory are appropriate for their intended purpose; that staff is proficient in the process; and that deviations from approved standards of practice do not occur without proper authorization;

(9) standards for data recording, review, storage and reporting that include, but are not limited to standards to ensure:

(a) that data is recorded promptly, directly, legibly and accurately with a review to verify that applicable standards of practice, equipment calibration and reference standards were applied before reporting;

(b) that all data, including raw data, documentation, protocols and reports are retained for two years, protected from unauthorized alteration and retrievable as needed by authorized personnel; and

(c) that reports are the property of the business or individual who provided the sample and must contain the date of receipt of the sample, form of the sample, sample identifier, chain of custody, date of analysis, method used, testing results, laboratory information, individual responsible for verifying the results and a statement that the results apply only to the sample received;

(10) current material safety data sheets for all chemicals used; and

(10) such other materials as the department may require.

**(E) Proficiency testing and inspection:**

(1) A laboratory applicant shall be subject to proficiency testing by the department prior to approval, and an approved laboratory shall be subject to proficiency testing, at a frequency and at times to be determined by the program manager. A laboratory applicant or approved laboratory shall cooperate with the department for purposes of conducting proficiency testing. The department may require submission of cannabis and cannabis-derived product samples from licensed non-profit producers for purposes of proficiency testing.

(2) A laboratory applicant and an approved laboratory shall be subject to inspection(s), at times determined by the program manager, in accordance with the provisions of this rule. The department may require the inspection of premises, equipment, and written materials, to determine compliance with this rule, and to determine compliance with the application submissions of the laboratory applicant or approved laboratory, including but not limited to standard operating procedures and standards for testing.

(3) **Failure of proficiency testing:** If the department determines on the basis of a proficiency test that a laboratory applicant has not satisfactorily identified the presence, quantity or other relevant factor(s)

pertaining to a given analyte, the department may deny the application in whole or in part, require additional tests, or require remedial actions to be taken by the laboratory applicant. If the department determines on the basis of a proficiency test that an approved laboratory has not satisfactorily identified the presence, quantity or other relevant factor(s) pertaining to a given analyte, the department may withdraw approval of the laboratory in whole or in part, require additional tests, or require remedial actions to be taken by the approved laboratory.

(F) **Retention and inspection of testing records:** An approved laboratory shall maintain all results of laboratory tests conducted on cannabis or cannabis derived products and shall make them available to the program upon the program's request.

(G) **Identification cards:** Identification cards issued by the department are the property of the department and shall be returned to the department upon the termination of the holder's employment with the approved laboratory, upon suspension or revocation, or upon demand of the department.

(H) **Term of approval:** Department approval of a laboratory for purposes of this rule shall be for a term of one year, and shall expire after that year, or upon closure of the approved laboratory. An approved laboratory shall apply for renewal of approval annually no later than thirty (30) days prior to expiration.

(I) **Termination:** The department may deny, withdraw or suspend approval of a laboratory in accordance with this rule, upon determination by the department that the laboratory has violated a provision of this rule, upon failure of a proficiency test, upon the refusal of the laboratory to provide requested access to premises or materials, or for upon the failure of a laboratory to comply with any standard, procedure, or protocol developed, submitted or maintained pursuant to this rule.

[7.34.4.15 NMAC - N, 7/15/2014]

#### **7.34.4.16 DEPARTMENT-APPROVED COURIERS; GENERAL PROVISIONS:**

A. **Approval of couriers:** The department may approve a courier for the purpose of transporting usable cannabis from one or more licensed non-profit producers to qualified patients and primary caregivers.

B. **Application requirements:** An applicant who seeks department approval to operate as a courier shall provide the following materials and information to the department in order to be considered for approval; and an approved courier shall promptly submit revisions in the event that the materials or information changes:

- (1) a plan for delivery;
- (2) a plan for security, including a description of facilities and containers intended for use in storing and transporting usable cannabis;
- (3) a plan for safety, to include at a minimum a description of measures to be taken by the courier and its employees to ensure the safety of qualified patients, primary caregivers, and courier staff;
- (4) a description of all vehicles used or intended to be used for the transport of usable cannabis;
- (5) a complete list of employees;
- (6) clear, legible photocopies of current New Mexico state-issued identification cards of all courier personnel;
- (7) completed nationwide and statewide criminal history screening documentation;
- (8) a description of the courier's hours of operation;
- (9) a description of the locations or type(s) of locations where the courier will offer delivery of usable cannabis;
- (10) a description of all licensed non-profit producers for whom the courier will deliver usable cannabis, and copies of all agreements between the courier and licensed non-profit producers for the delivery of usable cannabis;
- (11) a description of all fees to be charged by the courier;
- (12) protocols for contacting and communicating with qualified patients and primary caregivers regarding deliveries;
- (13) training materials for drivers;
- (14) confidentiality training materials that address the confidentiality of qualified patient and primary caregiver information;
- (15) proof that the non-profit entity is in good standing with the New Mexico taxation and revenue department;
- (16) copies of the applicant's articles of incorporation or organization, as applicable;
- (17) copies of the applicant's by-laws, as applicable;
- (18) a list of all persons or business entities having direct or indirect authority over the management or policies of the courier, as applicable;

(19) a list of all persons or business entities having any ownership interest in any property utilized by the courier, whether direct or indirect, whether the interest is in land, building(s), or other material;

(20) proof that no buildings to be used by the courier are located within three hundred (300) feet of any school, church or daycare center;

(21) if the courier will base its business at a location that is not owned by the applicant: a written statement from the property owner or landlord of the location that grants to the courier permission to possess cannabis on the premises;

(22) an attestation that the courier will not distribute cannabis within three hundred (300) feet of a school, church or daycare center; and

(23) an attestation that no firearms will be permitted on any premises or in any vehicle used by the courier, and that no employee will possess a firearm when transporting or distributing cannabis.

**C. General requirements:** An approved courier shall adhere to each of the following requirements:

(1) A courier may contract with a licensed non-profit producer to deliver usable cannabis from the non-profit producer to a qualified patient or primary caregiver. A courier that provides service to more than one licensed non-profit producer shall offer their service at a uniform price for all non-profit producers for whom they deliver. An approved courier shall not transport a cannabis product that is not individually packaged, or that is not labeled in accordance with this rule.

(2) An approved courier shall not request or receive payment from a qualified patient or primary caregiver. A courier may collect any applicable fee from a licensed non-profit producer.

(3) Upon obtaining a package of usable cannabis from a licensed non-profit producer, an approved courier shall hold the package in a secured area or areas that are locked and otherwise resistant to tampering or theft, until the package is delivered to its intended recipient or returned to the licensed non-profit producer.

(4) An approved courier shall not relinquish possession of usable cannabis that is intended for delivery to a qualified patient or primary caregiver unless and until the package of usable cannabis is either successfully delivered, or returned to the licensed non-profit producer. For purposes of this section, a package of usable cannabis is successfully delivered only upon the approved courier's verification that an intended recipient has taken actual, physical possession of the package. An approved courier shall not leave a package at any location for any reason, unless the package is successfully delivered to its intended recipient.

(5) An approved courier shall not deliver a package to any person who is not identified by a selling licensed non-profit producer as a purchasing qualified patient or primary caregiver.

(6) At the time of delivery, an approved courier shall verify the recipient's identity by requiring presentation of the qualified patient's or primary caregiver's department-issued medical cannabis identification card and New Mexico-issued photo identification card or a passport. An approved courier shall not deliver usable cannabis to any person whose identity is not verified in accordance with this rule. An approved courier shall document having verified the recipient's identification in accordance with this rule for each transaction.

(7) An approved courier shall not possess usable cannabis for a time period greater than twenty-four (24) hours. An approved courier shall return any usable cannabis that is not successfully delivered to its intended recipient to a licensed non-profit producer within this time period.

(8) An approved courier shall not distribute cannabis within three hundred (300) feet of a school, church or daycare center.

(9) An approved courier and its personnel shall at all times take measures to ensure confidentiality and safety in the transport and delivery of usable cannabis to a qualified patient or primary caregiver.

(10) An approved courier shall appropriately train its personnel regarding the confidentiality of information concerning qualified patients and primary caregivers. Confidentiality training shall describe confidentiality requirements applicable under both federal and state law. An approved courier shall conduct confidentiality training of its personnel at least once annually, and shall maintain training materials on its premises, and document the training of individual staff.

(11) Personnel of an approved courier shall not possess a firearm while distributing or otherwise possessing cannabis. An approved courier shall not possess or permit the possession of a firearm on any premises, including a building or vehicle, utilized by the courier.

**D. Identification cards:** The department shall issue an identification card to each authorized employee of an approved courier authorizing that individual to transport cannabis from a non-profit producer to a qualified patient or primary caregiver. An employee of an approved courier shall carry the card at all times that the person transports cannabis, and shall present the card to law enforcement officials upon request. Identification cards issued by the department are the property of the department and shall be returned to the department upon an

approved courier's withdrawal from the program, upon the termination of a card holder's employment with the approved courier, upon suspension or revocation, or upon demand of the department.

**E. Term of approval:** Department approval of a courier shall be for a term of one year, and shall expire after that year, or upon closure of the courier. A courier shall apply for renewal of approval annually no later than thirty (30) days prior to expiration.

**F. Chain of custody:** A courier shall adopt, maintain and enforce chain of custody procedures and documentation requirements to ensure appropriate tracking and inventory of usable cannabis. A courier shall also adopt, maintain and enforce security requirements to ensure that usable cannabis transported by the courier is secured, and to promote the safety of courier personnel, as well as qualified patients and primary caregivers who receive packages from the courier.

**G. Confidentiality:** An approved courier may obtain contact information of a purchasing qualified patient or primary caregiver, as permitted by agreement between the courier and a respective licensed non-profit producer, and may utilize such information solely for the purpose of arranging a delivery location and time with the qualified patient or primary caregiver. An approved courier shall not otherwise disseminate, disclose or use identifying information or contact information concerning a qualified patient or primary caregiver.

[7.34.4.16 NMAC - N, 7/15/2014]

#### **7.34.4.17 QUALIFIED PERSONAL PRODUCTION APPLICATION AND LICENSURE**

##### **REQUIREMENTS:**

**A.** A qualified patient may apply for a personal production license to produce medical cannabis solely for the qualified patient's own use.

**B.** A qualified patient may obtain no more than one personal production license, which license may be issued for production to occur either indoors or outdoors in no more than one single location, which shall be either the patient's primary residence, or other property owned by the patient.

**C.** Only one No more than two personal production licenselicenses may be issued for a given location, absentwith proof that more-than-onea second registered patient currently resides at the location. Multiple personal production licenses may not be issued for non-residential locations.

**D.** Qualified patients shall provide the following in order to be considered for a personal production license to produce medical cannabis:

(1) appropriateapplicable non-refundable fee Paragraph (3) of Subsection Q of 7.34.4.8 NMAC;

(2) a description of the single indoor or outdoor location that shall be used in the production of cannabis;

(3) if the location is on property that is not owned by the applicant: a written statement from the property owner or landlord that grants to the applicant permission to grow cannabis on the premises;

(4) completed nationwide and statewide criminal history screening documentation;

(5) a written plan that ensures that the cannabis production shall not be visible from the street or other public areas;

(4) (6) a written acknowledgement that the applicant will ensure that all cannabis, cannabis-derived products and paraphernalia is kept secure and out of reach of children;

(7) a description of any device or series of devices that shall be used to provide security and proof of the secure grounds; and

(58) a written acknowledgement of the limitations of the right to use and possess cannabis for medical purposes in New Mexico.

[7.34.4.914 NMAC - N, 12/30/2010]

Rp. 7.34.4.1017 NMAC. 7/15/2014]

#### **7.34.4.18 NON-PROFIT PRIVATE ENTITY PRODUCTION APPLICATION AND LICENSURE**

**REQUIREMENTS:** A private non-profit entity shall provide the following materials and information to the department in order to be considered for a license to produce medical cannabis. A licensed non-profit entity shall also promptly submit revised versions of the following materials in the event that the materials or their content change.

**A. Organizational information and materials:** A private non-profit entity shall submit to the department:

(1) proof that the private entity is a non-profit corporation in good standing with the PRC pursuant to Section 53-8-1 *et seq.* NMSA 1978;

- ~~(2) copies of \_\_\_\_\_ proof that the non-profit entity is in good standing with the New Mexico taxation and revenue department;~~
- ~~(3) copies of the entity's articles of incorporation;~~
- ~~(34) copies of the entity's by-laws;~~
- ~~(45) verification that the board of directors of the non-profit includes, at a minimum, five (5) voting members, including one (1) medical provider limited to a physician (MD or OD), a registered nurse, nurse practitioner, licensed practical nurse or physician assistant, and three (3) patients currently qualified under department regulations and the Lynn and Erin Compassionate Use Act, NMSA 1978, Section 26-2B-1 et seq.;~~
- ~~(5) a list of all persons or business entities having direct or indirect authority over the management or policies of the facility;~~
- ~~(6) a list of all persons or business entities having five percent or more direct or indirect authority over the management or policies of the private entity;~~
- ~~(7) a list of all persons or business entities having any ownership interest in any property utilized by the facility non-profit entity, whether direct or indirect, and whether the interest is in land, building(s), or other material, including owners of any business entity which that owns all or part of the land or building(s) utilized;~~
- ~~(78) the identities and financial information, including information concerning loans and monetary investments, of all creditors currently holding a security interest in the non-profit entity or premises of the privatenon-profit entity, if any; and~~
- ~~(89) a brief business plan showing how the private entity willintends to fund its operations during the first two years of licensing, including and become a successful producer, including information concerning personnel, horticulture, technology and funding sources.~~

**B. Production and distribution information and materials:** A private non-profit entity shall submit to the department:

- ~~(1) an acknowledgement that production, at any time, shall not exceed atthe total of one hundred and fifty (150) mature female plants, seedlings, cuttings, and clones, and male plants that the non-profit entity has been approved to produce as well as an inventory of usable cannabis that reflects current patient needs;~~
- ~~(2) a production plan that includes the non-profit entity's plan for the growth, cultivation and harvesting of medical cannabis;~~
- ~~(3) a written set of distribution criteria for qualified patients or primary caregivers appropriate for cannabis services that describes the method by which and locations at which distribution will occur, and that includes a clear identifiable photocopy of all qualified patient's or the primary caregiver's registry identification card served by the private entity;~~
- ~~(34) a complete written description of the means that the private non-profit shall employ to safely dispense the cannabis and cannabis-derived products to qualified patients or theand qualified patient'spatients' primary caregivers;~~
- ~~(4) (5) an attestation that qualified patients shall not be permitted to consume cannabis or cannabis-derived products on the entity's property;~~
- ~~(6) an attestation that the entity will require the presentation of a department-issued identification card and a valid New Mexico photo identification card or a passport prior to selling or otherwise distributing cannabis or cannabis derived products to qualified patients and primary caregivers;~~
- ~~(7) a description and sample of the packaging of the useableusable cannabis and cannabis-derived products that the private non-profit entity shall utilize, including a label that shall contain the name of the strain, batch, quantity and a statement that the product is for medical use and not for resale; and~~
- ~~(5) a descriptionsatisfies the labeling requirements of the testing procedures the private entity shall use to determine the quality of medical cannabis produced or distributed this rule; and~~
- ~~(8) a written quality assurance plan.~~

**C. Facility information:** A private non-profit entity shall submit to the department:

- ~~(1) a description of the facilityfacilities and equipment that shall be used in the production and distribution of cannabis;~~
- ~~(2) proof that the facility isfacilities are not within three hundred (300) feet of any school, church or daycare center; and~~
- ~~(3) a description of the methods and device or series of devices that shall be used to provide security.~~

**D. Educational methods and materials:** A private non-profit entity shall submit to the department:

- ~~(1) a description of the private entity's means for educating the qualified patient and the primary caregiver on the limitation of the right to possess and use cannabis;~~

- (2) a description of the means the private entity shall employ to make qualified patients or the primary caregiver aware of the quality of the product;
  - (3) a description of ingestion options of ~~useable~~usable cannabis provided by the private entity;
  - (4) a description of ~~safe smoking inhalation~~ techniques that shall be provided to qualified patients;
- and
- (5) a description of potential side effects and how the private entity will educate qualified patients and the qualified patient's primary caregivers regarding potential side effects.

~~(6) a description of the means the private entity shall employ to make qualified patients or the primary caregiver aware of how to report adverse events related to medical cannabis use; and~~

~~(7) a description of the means the private entity shall employ to make qualified patients or the primary caregiver aware of how to report concerns regarding the private entity's products and services.~~

**E. Sales ~~records~~record forms:** A private non-profit entity shall submit to the department a sample of the private entity's sales record form(s), which shall identify (among other items) the name of the purchaser, the date of the sale, and the quantity and price of medical cannabis sold.

~~(1) a profit and loss statement and balance sheet submitted quarterly and as requested by the department;~~

~~(2) a current business license and tax and revenue registration certificate.~~

**F. Policies and procedures:** A private non-profit entity shall submit to the department copies of policies and procedures developed, implemented and maintained on the premises of the private entity's facility. A non-profit entity shall verify that the private entity will comply with the stated terms of the policies and procedures as written and submitted to the department.

**G. Personnel records:** A private non-profit entity shall submit to the department:

~~(1) separate nationwide and statewide criminal history screening documentation for all individuals associated, in accordance with the private entity's production facility, to include board members, persons having direct or indirect authority over management or policies, employees, and volunteers; provisions of this rule;~~

(2) samples of the personnel records retained by the private entity for each employee as required by this rule, including:

(a) a sample application for employment;

~~(b) sample record of any disciplinary action taken state and federal employment documentation;~~

(c) a sample written job descriptions or employment contracts developed for all employee positions, to include duties, authority, responsibilities, qualifications and supervision;

~~(d) payment or payroll records for all individuals associated with the private entity's production and distribution facility, to include board members, persons having direct or indirect authority over management or policies, and employees submitted quarterly and as requested by the department;~~

(3) an on-site training curriculum (unless the private entity intends to enter into contractual relationships with outside resources capable of meeting employee training needs) that addresses, at a minimum, the following topics:

(a) state and federal confidentiality laws, including HIPAA;

(b) professional conduct and ethics;

~~(c) the Lynn and Erin Compassionate Use Act and Department of Health rules;~~

~~(d) informational developments in the field of medical use of cannabis; and~~

~~(de) employee safety and security training addressing, at a minimum, the proper use of the security measures and controls that have been adopted, and specific procedural instructions on how to respond to an emergency, including a robbery or violent accident; and~~

(4) proof of HIPAA certification for all individuals associated with ~~at~~the private entity ~~production facility~~, including all board members, persons having direct or indirect authority over management or policies, ~~and employees, and volunteers.~~

**H. Other materials:** A private non-profit entity shall submit to the department:

~~(1) a description of the department approved laboratory or laboratories that the non-profit entity will utilize for testing usable cannabis in accordance with this rule, and the type(s) of testing that the approved laboratory or laboratories will perform for the non-profit entity;~~

~~(2) the name of any courier that the non-profit entity intends to use for transport of usable cannabis to qualified patients and primary caregivers; and~~

~~(3) such other information as the private entity wishes to provide ~~or~~and such other information as the department may reasonably request.~~

**I. Patient identification and sales records:** A private non-profit entity shall retain clear, legible photocopies of all registry identification cards and New Mexico photo identification cards of all qualified patients and primary caregivers served by the non-profit entity. A private non-profit entity shall also create and retain materials that document every instance in which usable cannabis was sold or otherwise distributed to another person or entity, including documentation of the recipient, type, quantity, and batch of the usable cannabis.

**J. Material safety data sheets:** A private non-profit entity shall maintain current material safety data sheets on-site for all chemicals used, including but not limited to cleaning compounds, sanitizing agents, and pesticides.

**K. Local ordinance:** A licensed non-profit entity shall comply with all applicable local ordinances, including but not limited to zoning, occupancy, licensing and building codes.

[7.34.4.4015 NMAC - N, 12/30/2010]

Rp. 7.34.4.418 NMAC, 7/15/2014]

**7.34.4.19 SECURITY REQUIREMENTS FOR LICENSED PRODUCERS:** Private non-profit entities licensed to produce medical cannabis shall comply with the following requirements to ensure that production and distribution facilities are located on secure grounds.

**A.** The licensed private non-profit entity shall provide and maintain in each facility a fully operational security alarm system.

**B.** The licensed private non-profit entity shall conduct a monthly maintenance inspection and make all necessary repairs to ensure the proper operation of the alarm system and, in the event of an extended mechanical malfunction that exceeds an eight (8) hour period, provide alternative security that shall include closure of the premises.

**C.** The licensed private non-profit entity shall maintain documentation for a period of at least twenty-four (24) months of all inspections, servicing, alterations and upgrades performed on the security alarm system; all documentation shall be made available within twenty-four (24) hours of a department representative's request; failure to provide equipment maintenance documentation within the twenty-four (24) hour period shall subject the licensed producer to the sanctions and penalties provided for in this rule; the twenty-four (24) hour period shall not include holidays and weekends.

[7.34.4.416 NMAC - Rp, 7.34.4.919 NMAC, 12/30/2010/7/15/2014]

**7.34.4.12 DENIAL OF AN INITIAL PRODUCER LICENSE:**

**A. Administrative review of license application denials:** An applicant whose initial application for a producer license is denied by the medical cannabis program manager or designee may request an administrative review by the administrative review committee. The written notice of denial shall include a statement of the right to request such a review.

**B. No administrative review of determinations made by the secretary:** An applicant whose initial application for a producer license was for any reason not approved by the secretary (rather than the program manager or designee) shall not be entitled to further review by the department, but may reapply at a later date.

**C. Procedure for requesting informal administrative review:**

**(1)** An applicant given notice of an application denial by the medical cannabis program manager or designee may submit a written request for a record review. To be effective, the written request shall:

**(a)** be made within thirty (30) calendar days, as determined by the postmark, from the date of the denial notice issued by the department;

**(b)** be properly addressed to the medical cannabis program;

**(c)** state the applicant's name, address, and telephone numbers;

**(d)** state the applicant's proposed status as a licensed producer; and

**(e)** provide a brief narrative rebutting the circumstances of the application denial.

**(2)** If the applicant wishes to submit additional documentation for consideration, the applicant shall include such additional documentation when submitting the request for administrative review.

**D. Administrative review proceeding:** The administrative review proceeding shall be a closed proceeding that is limited to an administrative review of written application materials and documents offered to verify eligibility. The administrative review is not an adjudicatory hearing. The administrative review shall be conducted by the administrative review committee. In cases where the administrative review committee finds the need for additional or clarifying information, the review committee shall request that the applicant supply such additional information within the time set forth in the committees' request.

~~\_\_\_\_\_ E. \_\_\_\_\_~~ **Final determination:**

~~\_\_\_\_\_ (1) \_\_\_\_\_~~ Content. The administrative review committee shall render a written decision setting forth the reasons for the decision.

~~\_\_\_\_\_ (2) \_\_\_\_\_~~ Effect. The decision of the administrative review committee is the final decision of the informal administrative review proceeding.

~~\_\_\_\_\_ (3) \_\_\_\_\_~~ Notice. A copy of the decision shall be mailed to the applicant.

~~\_\_\_\_\_ F. \_\_\_\_\_~~ **Judicial review:** Except as otherwise provided by law, there shall be no right to judicial review of a decision by the program manager or designee, the administrative review committee, or the secretary. [7.34.4.12 NMAC - Rp, 7.34.4.10 NMAC, 12/30/2010]

~~7.34.4.13 \_\_\_\_\_~~ **PARENTAL RESPONSIBILITY ACT:** The failure to comply with a judgment or order for child support, or subpoena or warrants relating to paternity or child support proceedings, is grounds for the denial, suspension or revocation of a private entity's license to produce medical cannabis in accordance with Section 40-5A-6, NMSA 1978, of the Parental Responsibility Act. [7.34.4.13 NMAC - Rp, 7.34.4.11 NMAC, 12/30/2010]

**7.34.4.1420 PROHIBITIONS, RESTRICTIONS AND LIMITATIONS ON THE PRODUCTION AND DISTRIBUTION OF MEDICAL CANNABIS AND CRIMINAL PENALTIES:**

**A.** Participation in the medical cannabis licensing program by a licensed producer, or the employees ~~or contractors~~ of a licensed producer, does not relieve the producer ~~or~~ employee ~~or contractor~~ from criminal prosecution or civil penalties for activities not authorized in this rule and the act.

**B. Locations of production and distribution:** Production of medical cannabis and distribution of medical cannabis to qualified patients or their primary caregivers shall take place at locations (or, with respect to distribution, categories of locations) described in the non-profit entity's production and distribution plan approved by the department, and shall not take place at locations that are within three hundred (300) feet of any school, church or daycare center.

**C. Fraudulent misrepresentation:** Any person who makes a fraudulent representation to a law enforcement officer about the person's participation in the medical cannabis program to avoid arrest or prosecution for a cannabis-related offense is guilty of a petty misdemeanor and shall be sentenced in accordance with the provisions of Section 31-19-1 *et seq.*, NMSA 1978.

**D. Unlawful distribution:** If a licensed producer or employee of a licensed producer sells, distributes, dispenses or transfers cannabis to a person not approved by the department pursuant to this rule and the act, or obtains or transports cannabis outside New Mexico in violation of federal law, the licensed producer or employee of the licensed producer shall be subject to arrest, prosecution and civil or criminal penalties pursuant to state law.

**E. Revocation of registry identification card, licensed primary caregiver card, license to produce or distribute:** Violation of any provision of this rule may result in ~~the immediate revocation of any privilege granted under this rule and the act-disciplinary action, in accordance with this rule.~~

[7.34.4.1417 NMAC - Rp, 7.34.4.1220 NMAC, 12/30/2010/15/2014]

**7.34.4.1521 MONITORING AND CORRECTIVE ACTIONS:**

**A. Monitoring:**

(1) The department or its designee may perform on-site assessments of a licensed producer ~~or producer-applicant, an approved manufacturer or manufacturer-applicant, an approved laboratory or a laboratory-applicant, and an approved courier or courier-applicant,~~ to determine compliance with these rules: ~~or submissions made pursuant to this rule.~~ The department may enter ~~a facility~~ the premises of a licensed producer, approved manufacturer, approved laboratory or approved courier at any time to assess or monitor.

(2) Twenty-four (24) hours' notice shall be provided to ~~licensed producers who are qualified patients~~ personal production license holders prior to an on-site assessment, except when the department has ~~reasonable suspicion~~ reason to believe that providing notice will result in the destruction of evidence or that providing such notice will impede the department's ability to enforce these regulations.

(3) The department may review any and all ~~employee records of a licensed non-profit producer, a qualified patient or primary caregiver records or,~~ an approved manufacturer, approved laboratory, and approved courier, and may require and conduct interviews with ~~employees, qualified patients, primary caregivers or private licensed producers~~ such persons or entities and persons affiliated with such entities, for the purpose of determining compliance with ~~these requirements~~ department rules and applicable laws.

(4) All licensed producers, ~~approved manufacturers, approved laboratories and approved couriers~~ shall provide the department or the department's designee immediate access to any material and information necessary for determining compliance with ~~these requirements~~ this rule.

(5) Failure by ~~the~~ licensed producer, ~~approved manufacturer, approved laboratory, or approved courier~~ to provide the department access to the premises or ~~information~~ materials may result in ~~the revocation of the licensed producer's license and referral to state law enforcement~~ disciplinary action(s), in accordance with this rule.

(6) Any failure to adhere to these rules that is documented by the department during monitoring may result in ~~sanction(s), including suspension, revocation, non-renewal or denial of licensure and referral to state or local law enforcement~~ disciplinary action, in accordance with this rule.

(7) The department shall refer ~~non-frivolous~~ complaints ~~involving alleged~~ alleging criminal activity ~~that are made against a licensed producer to the, approved manufacturer, approved laboratory or approved courier to~~ appropriate New Mexico state or local law enforcement authorities.

**B. Financial records:** A licensed non-profit private entity shall maintain detailed confidential sales records in a manner and format approved by the department, and shall inform the department of the location where such records are kept, and promptly update that information if the records are removed.

(1) **Access:** The department ~~or~~ and its agents shall have reasonable access to the sales and other financial records of a ~~private entity licensee~~ licensed non-profit producer, and shall be granted immediate access to those records upon request. A patient shall be granted reasonable access to a licensed non-profit producer's sales records ~~off~~ for that patient upon request.

(2) **Audit:** A licensed non-profit private entity shall submit the results of an annual financial audit to the department no later than ~~January 31st of each year~~ sixty (60) days after the end of each fiscal year of the licensed non-profit. For the purposes of this section, the fiscal year of a non-profit producer shall be the twelve-month cycle identified by the producer in its filings with the New Mexico taxation and revenue department. The annual audit shall be conducted by an independent certified public accountant; the costs of any such audit shall be borne by the private entity. Results of the annual audit shall be forwarded to the medical cannabis program manager or designee. The department may also periodically require, within its discretion, the audit of a non-profit private entity's financial records by the department.

(3) **Quarterly reports:** A non-profit producer shall submit reports on at least a quarterly basis, or as otherwise requested, and in the format specified by the department.

**C. Corrective action:**

(1) If violations of requirements of this rule are cited as a result of monitoring or review of financial records, the licensed producer shall be provided with an official written report of the findings within seven (7) business days following the monitoring visit or the review of financial records.

(2) Unless otherwise specified by the department, the licensed producer shall correct the violation within five (5) calendar days of receipt of the official written report citing the violation(s).

(3) The violation shall not be deemed corrected until the department verifies in writing within seven (7) calendar days of receiving notice of the corrective action that the corrective action is satisfactory.

(4) If the violation has not been corrected, the department may issue a notice of contemplated action to suspend, revoke, or take other disciplinary action against the ~~producer's license~~ producer's license, in accordance with the provisions of this rule.

**D. Suspension of license without prior hearing:** ~~In accordance with the Public Health Act, Section 24-1-5 (H) NMSA 1978,~~ If immediate action is required to protect the health and safety of the general public, ~~the~~ a qualified patient, or ~~a primary caregiver~~ caregiver, the program manager or designee may suspend the qualified patient, primary caregiver or licensed producer's license without notice:

~~(1) A licensee whose license has been summarily suspended is entitled to a record review not later than thirty (30) calendar days after the license was summarily suspended.~~

~~(2) The record review requested subsequent to a summary suspension shall be conducted by the administrative review committee.~~

~~(3) The administrative review committee shall conduct the record review on the summary suspension by reviewing all documents submitted by both licensee and the department.~~

~~(4) The sole issue at a record review on a summary suspension is whether the licensee's license shall remain suspended pending a final adjudicatory hearing and subsequent ruling by the secretary.~~

~~(5) A licensee given notice of summary suspension by the division, or may submit a written request immediately withdraw approval for a record review. To be effective, the written request shall:~~ laboratory, manufacturer, or courier without notice.

- ~~\_\_\_\_\_ (a) be made within thirty (30) calendar days, from the date of the notice issued by the department, as determined by the postmark;~~
- ~~\_\_\_\_\_ (b) be properly addressed to the medical cannabis program;~~
- ~~\_\_\_\_\_ (c) state the applicant's name, address, and telephone numbers;~~
- ~~\_\_\_\_\_ (d) provide a brief narrative rebutting the circumstances of the suspension, and~~
- ~~\_\_\_\_\_ (e) include attachments of any additional documentation that the individual wishes to be considered in the record review;~~

[7.34.4.15 NMAC - Rp, 7.34.4.1321 NMAC, 12/30/2010/7/15/2014]

**7.34.4.1622 DISCIPLINARY ACTIONS AND APPEAL PROCESS:**

~~A. **Revocation of producer license:** Violation of any provision of this rule may result in either the summary suspension of a producer's license by the medical cannabis program manager or designee, or issuance of a notice of contemplated action by the program manager or designee to suspend, revoke or take other disciplinary action against the producer's license and revoke (or otherwise affect) lawful privileges under the Lynn and Erin Compassionate Use Act, NMSA 1978, Section 26-2B-1 et seq.~~

~~BA. **Grounds for disciplinary action.** A license may be revoked or suspended, or have other; Disciplinary action may be taken against it, and a renewal a producer-applicant, a licensed producer, a manufacturer-applicant or approved manufacturer, a laboratory applicant or approved laboratory, or an approved courier or courier-applicant. Disciplinary action may include revocation, suspension, or denial of an application, license, or department approval, and other action. Disciplinary action may be denied;imposed for:~~

- ~~(1) failure to comply with or satisfy any provision of this rule;~~
- ~~(2) failurefalsification or misrepresentation of any material or information submitted to the department;~~
- ~~(3) failing to allow or impeding a monitoring visit by authorized representatives of the department;~~
- ~~(3) falsification of any material or information submitted to the department;~~
- ~~(4) failure to adhere to any acknowledgement, verification or other representation made to the department;~~
- ~~(5) failure to submit or disclose information required by this rule or otherwise requested by the department;~~
- ~~(6) failure to correct any violation of this rule cited as a result of a review or audit of financial records or other materials;~~
- ~~(7) failure to comply with the department's requested access to premises or materials;~~
- ~~(8) failure to pay a required monetary penalty;~~
- ~~(9) diversion of cannabis or a cannabis-derived product, as determined by the department; and~~
- ~~(510) threatening or harming a patient, a medical practitioner, or an employee of the department.; and~~

~~C. **Request for hearing:** A (11) any other basis identified in this rule.~~

~~B. **Fines:** Disciplinary actions against a licensed non-profit producer, approved manufacturer, approved laboratory or approved courier may include the imposition of monetary penalties, which may be assessed by the department in the amount of:~~

- ~~(1) one-hundred dollars (\$100) for the first assessed monetary penalty in a calendar year;~~
- ~~(2) five hundred dollars (\$500) for the second assessed monetary penalty in a calendar year;~~
- ~~(3) one-thousand dollars (\$1,000) for every monetary penalty thereafter assessed in a calendar year.~~

~~C. **Persons and entities who may request a hearing:** The following persons or entities may request a hearing to contest an action or proposed action of the department, in accordance with this rule:~~

- ~~(1) A licensed producer whose license has been summarily suspended or who has received a notice of contemplated action to suspend, revoke or take other disciplinary action may request a hearing, in addition to a request for an administrative review of written materials (as applicable), for the purpose of review of such action.;~~
- ~~(2) An initial personal production licensure applicant whose application is denied for any reason other than failure to submit a completed application or failure to meet a submittal requirement of this rule;~~
- ~~(3) An approved manufacturer whose approval status has been summarily suspended or who has received a notice of contemplated action to suspend, revoke or take other disciplinary action;~~
- ~~(4) A manufacturer-applicant whose application is denied for any reason other than failure to submit a completed application or failure to meet a submittal requirement of this rule;~~
- ~~(5) An approved laboratory whose approval status has been summarily suspended or who has received a notice of contemplated action to suspend, revoke or take other disciplinary action;~~